QUARTERLY REPORT

Q1 FY2027 — Quarterly report (Form 10-Q)

Q1 FY2027PDF · 84 pages703 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark one)
x True QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2026
OR
o False TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from 	to
THE PROCTER & GAMBLE COMPANY
(Exact name of registrant as specified in its charter)
Ohio 	OH 	1-434 	31-0411980
(State of Incorporation) 	(Commission File Number) 	(I.R.S. Employer Identification Number)
One Procter & Gamble Plaza 	Cincinnati 	OH
One Procter & Gamble Plaza, Cincinnati, Ohio 	45202
(Address of principal executive offices) 	(Zip Code)
(513) 983-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol 	Name of each exchange on which registered
Common Stock, without Par Value 	PG 	NYSE
0.110% Notes due 2026 	PG26D 	NYSE
4.875% EUR Notes due May 2027 	PG27A 	NYSE
1.200% Notes due 2028 	PG28 	NYSE
3.150% EUR Notes due 2028 	PG28B 	NYSE
1.250% Notes due 2029 	PG29B 	NYSE
1.800% Notes due 2029 	PG29A 	NYSE
6.250% GBP Notes due January 2030 	PG30 	NYSE
0.350% Notes due 2030 	PG30C 	NYSE
0.230% Notes due 2031 	PG31A 	NYSE
3.250% EUR Notes due 2031 	PG31B 	NYSE
5.250% GBP Notes due January 2033 	PG33 	NYSE
2.900% Notes due 2033 	PG33B 	NYSE
3.200% EUR Notes due 2034 	PG34C 	NYSE
1.875% Notes due 2038 	PG38 	NYSE
0.900% Notes due 2041 	PG41 	NYSE
3.650% Notes due 2045 	PG45 	NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of
"large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer 	þ 	Accelerated filer 	¨
Non-accelerated filer 	¨ 	Smaller reporting company 	¨ 	False
Emerging growth company 	¨ 	False
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ False
There were 2,317,783,143 shares of Common Stock outstanding as of September 30, 2026.

-- 1 of 84 --

FORM 10-Q TABLE OF CONTENTS 	Page
PART I 	Item 1. 	Financial Statements 	1
Consolidated Statements of Earnings 	1
Consolidated Statements of Comprehensive Income 	2
Consolidated Balance Sheets 	3
Consolidated Statements of Shareholders' Equity 	4
Consolidated Statements of Cash Flows 	5
Notes to Consolidated Financial Statements 	6
Note 1: Basis of Presentation 	6
Note 2: Segment Information 	6
Note 3: Goodwill and Intangible Assets 	7
Note 4: Earnings Per Share 	9
Note 5: Risk Management Activities and Fair Value Measurements 	9
Note 6: Commitments and Contingencies 	11
Note 7: Supplemental Information 	11
Note 8: Subsequent Event 	12
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations 	12
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	22
Item 4. 	Controls and Procedures 	22
PART II 	Item 1. 	Legal Proceedings 	23
Item 1A. 	Risk Factors 	23
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 	23
Item 5. 	Other Information 	23
Item 6. 	Exhibits 	25
Signature 	25

-- 2 of 84 --

The Procter & Gamble Company 1
PART I. FINANCIAL INFORMATION
Item 1. 	Financial Statements
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
Three Months Ended September 30
Amounts in millions except per share amounts 	2026 	2025
NET SALES 	$ 	23,276 $ 	22,386
Cost of products sold 	11,678 	10,887
Selling, general and administrative expense 	5,661 	5,643
OPERATING INCOME 	5,937 	5,856
Interest expense 	(223) 	(197)
Interest income 	102 	108
Other non-operating income/(expense), net 	207 	268
EARNINGS BEFORE INCOME TAXES 	6,023 	6,034
Income taxes 	1,267 	1,253
NET EARNINGS 	4,757 	4,781
Less: Net earnings attributable to noncontrolling interests 	26 	31
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	4,731 $ 	4,750
NET EARNINGS PER COMMON SHARE
Basic 	$ 	2.00 $ 	2.00
Diluted 	$ 	1.97 $ 	1.95
Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.

-- 3 of 84 --

2 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended September 30
Amounts in millions 	2026 	2025
NET EARNINGS 	$ 	4,757 $ 	4,781
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Change in defined benefit postretirement plans
Other comprehensive income/(loss) before reclassifications 	(7) 	(8)
Reclassifications to Consolidated Statement of Earnings 	5 	13
Total change in defined benefit postretirement plans, before tax 	(2) 	5
Income tax benefit/(expense) 	1 	(2)
Total change in defined benefit postretirement plans, net of tax 	(2) 	3
Change in foreign currency translation and other
Other comprehensive income/(loss) before reclassifications 	(182) 	(12)
Reclassifications to Consolidated Statement of Earnings 	— 	—
Total change in foreign currency translation and other, before tax 	(182) 	(12)
Income tax benefit/(expense) 	(5) 	(10)
Total change in foreign currency translation and other, net of tax 	(187) 	(22)
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX 	(189) 	(19)
TOTAL COMPREHENSIVE INCOME 	4,568 	4,762
Less: Comprehensive income attributable to noncontrolling interests 	24 	24
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	4,544 $ 	4,737
Postretirement benefit plan amounts are reclassified from Accumulated other comprehensive income/(loss) into Other non-operating income/(expense), net and included in
the computation of net periodic postretirement costs.
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.

-- 4 of 84 --

The Procter & Gamble Company 3
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
Amounts in millions 	September 30, 2026 	June 30, 2026
Assets
CURRENT ASSETS
Cash and cash equivalents 	$ 	15,365 $ 	9,942
Accounts receivable 	6,620 	6,056
INVENTORIES
Materials and supplies 	2,304 	2,143
Work in process 	1,107 	1,105
Finished goods 	5,074 	4,922
Total inventories 	8,485 	8,170
Prepaid expenses and other current assets 	2,038 	2,040
TOTAL CURRENT ASSETS 	32,508 	26,208
PROPERTY, PLANT AND EQUIPMENT, NET 	25,519 	25,360
GOODWILL 	41,197 	41,276
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 	21,359 	21,444
OTHER NONCURRENT ASSETS 	12,549 	12,231
TOTAL ASSETS 	$ 	133,132 $ 	126,521
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable 	$ 	17,056 $ 	16,306
Accrued and other liabilities 	10,911 	11,091
Debt due within one year 	17,028 	11,296
TOTAL CURRENT LIABILITIES 	44,996 	38,694
LONG-TERM DEBT 	21,897 	22,842
DEFERRED INCOME TAXES 	5,949 	5,760
OTHER NONCURRENT LIABILITIES 	4,954 	4,914
TOTAL LIABILITIES 	77,795 	72,210
SHAREHOLDERS’ EQUITY
Preferred stock 	747 	756
Common stock – shares issued – 	September 2026 	4,009.2
June 2026 	4,009.2 	4,009 	4,009
Additional paid-in capital 	69,700 	69,533
Reserve for ESOP debt retirement 	(555) 	(596)
Accumulated other comprehensive loss 	(12,652) 	(12,465)
Treasury stock 	(144,173) 	(143,008)
Retained earnings 	138,021 	135,852
Noncontrolling interest 	239 	230
TOTAL SHAREHOLDERS’ EQUITY 	55,337 	54,311
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 	$ 	133,132 $ 	126,521
See accompanying Notes to Consolidated Financial Statements.

-- 5 of 84 --

4 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Three Months Ended September 30, 2026
Dollars in millions except per share
amounts;
shares in thousands
Common Stock Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2026 	2,323,859 $4,009 	$756 	$69,533 	($596) 	($12,465) 	($143,008) $135,852 	$230 	$54,311
Net earnings 	4,731 	26 	4,757
Other comprehensive
income/(loss) 	(187) 	(2) 	(189)
Dividends and dividend
equivalents
($1.0885 per share):
Common 	(2,537) 	(2,537)
Preferred 	(72) 	(72)
Treasury stock purchases 	(8,591) 	(1,259) 	(1,259)
Employee stock plans 	1,545 	166 	87 	253
Preferred stock conversions 	970 	(8) 	1 	7 	—
ESOP debt impacts 	42 	47 	89
Noncontrolling interest, net 	— 	(15) 	(15)
BALANCE SEPTEMBER 30,
2026 	2,317,783 $4,009 	$747 	$69,700 	($555) 	($12,652) 	($144,173) $138,021 	$239 	$55,337
Three Months Ended September 30, 2025
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2025 	2,341,994 $4,009 	$777 	$68,770 	($672) 	($12,143) 	($138,702) $129,973 	$272 	$52,284
Net earnings 	4,750 	31 	4,781
Other comprehensive
income/(loss) 	(13) 	(6) 	(19)
Dividends and dividend
equivalents
($1.0568 per share):
Common 	(2,482) 	(2,482)
Preferred 	(73) 	(73)
Treasury stock purchases 	(8,025) 	(1,258) 	(1,258)
Employee stock plans 	1,954 	146 	110 	255
Preferred stock conversions 	811 	(7) 	1 	6 	—
ESOP debt impacts 	35 	44 	79
Noncontrolling interest, net 	— 	(16) 	(16)
BALANCE SEPTEMBER 30,
2025 	2,336,734 $4,009 	$770 	$68,917 	($637) 	($12,156) 	($139,845) $132,212 	$281 	$53,551
See accompanying Notes to Consolidated Financial Statements.

-- 6 of 84 --

The Procter & Gamble Company 5
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended September 30
Amounts in millions 	2026 	2025
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD 	$ 	9,942 $ 	9,556
OPERATING ACTIVITIES
Net earnings 	4,757 	4,781
Depreciation and amortization 	810 	761
Share-based compensation expense 	98 	121
Deferred income taxes 	115 	53
(Gain)/loss on sale of assets 	(20) 	(3)
Change in accounts receivable 	(589) 	(305)
Change in inventories 	(349) 	(303)
Change in accounts payable 	1,149 	648
Other 	(204) 	(344)
TOTAL OPERATING ACTIVITIES 	5,767 	5,408
INVESTING ACTIVITIES
Capital expenditures 	(1,366) 	(1,200)
Proceeds from asset sales 	27 	8
Acquisitions, net of cash acquired 	— 	(5)
Other investing activity 	(121) 	(338)
TOTAL INVESTING ACTIVITIES 	(1,460) 	(1,535)
FINANCING ACTIVITIES
Dividends to shareholders 	(2,603) 	(2,549)
Additions to short-term debt with original maturities of more than three months 	— 	1,123
Reductions in short-term debt with original maturities of more than three months 	(157) 	(1,800)
Net additions/(reductions) to other short-term debt 	5,758 	2,108
Reductions in long-term debt 	(747) 	(3)
Treasury stock purchases 	(1,250) 	(1,250)
Impact of stock options and other 	143 	134
TOTAL FINANCING ACTIVITIES 	1,144 	(2,239)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	(29) 	(20)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	5,423 	1,615
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD 	$ 	15,365 $ 	11,171
See accompanying Notes to Consolidated Financial Statements.

-- 7 of 84 --

6 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
The accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries ("the Company," "Procter & Gamble,"
"P&G," "we" or "our") should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026. We have
prepared these statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) pursuant to the rules and regulations
of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Note that certain columns and rows may not add due to rounding. In
the opinion of management, the accompanying Consolidated Financial Statements contain all normal recurring adjustments necessary to present fairly the
financial position, results of operations and cash flows for the interim periods reported. However, the results of operations included in such financial statements
may not necessarily be indicative of annual results.
There have been no new accounting pronouncements issued or effective during the three months ended September 30, 2026 that had, or are expected to have, a
material impact on our Consolidated Financial Statements.
2. Segment Information
Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and
5) Baby, Feminine & Family Care. Our five reportable segments are comprised of:
• Beauty: Hair Care (Conditioners, Shampoos, Styling Aids, Treatments); Personal Care (Antiperspirants and Deodorants, Personal Cleansing); Skin Care
(Facial Moisturizers, Cleaners and Treatments);
• Grooming: Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming);
• Health Care: Oral Care (Toothbrushes, Toothpastes, Other Oral Care); Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care);
• Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional,
Surface Care); Habitat Care (Pest Prevention, Outdoor Care); and
• Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Menstrual Care); Family Care
(Paper Towels, Tissues, Toilet Paper).
During the quarter ended September 30, 2026, the Company realigned its Fabric & Home Care reporting segment to include Habitat Care, which is now
operating under the Fabric & Home Care leadership team. Previously, the results of the Habitat Care business were reported in the Corporate segment. Certain
amounts in the prior year presentation between segments were reclassified to conform to the current year’s presentation.
Operating segments as a percentage of consolidated net sales are as follows:
% of Net sales by operating segment
Three Months Ended September 30
2026 	2025
Fabric Care 	23 % 	23 %
Home Care 	13 % 	12 %
Hair Care 	10 % 	10 %
Baby Care 	9 % 	9 %
Family Care 	8 % 	8 %
Grooming 	8 % 	8 %
Oral Care 	8 % 	8 %
Feminine Care 	6 % 	6 %
Personal Care 	6 % 	6 %
Personal Health Care 	6 % 	7 %
Other 	3 % 	3 %
Total 	100 % 	100 %
% of Net sales by operating segment excludes sales recorded in Corporate.
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 8 of 84 --

The Procter & Gamble Company 7
The following is a summary of reportable segment results:
Three Months Ended September 30, 2026
Beauty 	Grooming 	Health Care
Fabric & Home
Care
Baby, Feminine
& Family Care 	Corporate 	Total Company
Net sales 	$ 	4,410 $ 	1,889 $ 	3,318 $ 	8,204 $ 	5,322 $ 	132 $ 	23,276
Cost of products sold 	(1,770) 	(761) 	(1,318) 	(4,608) 	(2,970) 	(251) 	(11,678)
Selling, general and administrative expense 	(1,501) 	(509) 	(991) 	(1,515) 	(962) 	(183) 	(5,661)
Other segment items 	— 	— 	19 	— 	— 	67 	87
Earnings/(loss) before income taxes 	1,139 	619 	1,029 	2,080 	1,391 	(234) 	6,023
Net earnings/(loss) 	$ 	868 $ 	477 $ 	783 $ 	1,601 $ 	1,060 $ 	(32) $ 	4,757
Other segment information
Depreciation and amortization 	$ 	101 $ 	81 $ 	114 $ 	194 $ 	209 $ 	112 $ 	810
Capital expenditures 	$ 	89 $ 	220 $ 	134 $ 	204 $ 	291 $ 	429 $ 	1,366
Other segment items for each reportable segment includes interest expense, interest income and certain other non-operating income/(expense).
Three Months Ended September 30, 2025
Beauty 	Grooming 	Health Care
Fabric & Home
Care
Baby, Feminine
& Family Care 	Corporate 	Total Company
Net sales 	$ 	4,143 $ 	1,817 $ 	3,220 $ 	7,870 $ 	5,171 $ 	165 $ 	22,386
Cost of products sold 	(1,625) 	(743) 	(1,344) 	(4,192) 	(2,770) 	(214) 	(10,887)
Selling, general and administrative expense 	(1,387) 	(489) 	(945) 	(1,670) 	(955) 	(198) 	(5,643)
Other segment items 	— 	— 	6 	— 	— 	172 	178
Earnings/(loss) before income taxes 	1,132 	585 	937 	2,008 	1,446 	(75) 	6,034
Net earnings/(loss) 	$ 	879 $ 	463 $ 	718 $ 	1,553 $ 	1,105 $ 	61 $ 	4,781
Other segment information
Depreciation and amortization 	$ 	102 $ 	79 $ 	106 $ 	189 $ 	207 $ 	78 $ 	761
Capital expenditures 	$ 	74 $ 	132 $ 	109 $ 	291 $ 	274 $ 	319 $ 	1,200
Other segment items for each reportable segment includes interest expense, interest income and certain other non-operating income/(expense).
The Chief Operating Decision Maker (CODM) does not use assets by segment to evaluate performance or allocate resources. Therefore, we do not disclose
assets by segment.
3. Goodwill and Intangible Assets
Goodwill is allocated by reportable segment as follows:
Beauty 	Grooming 	Health Care
Fabric & Home
Care
Baby, Feminine &
Family Care 	Total Company
GOODWILL AT JUNE 30, 2026 	$ 	14,073 $ 	12,887 $ 	7,884 $ 	1,838 $ 	4,595 $ 	41,276
Acquisitions and divestitures 	— 	— 	— 	— 	— 	—
Translation and other 	(28) 	(20) 	(20) 	(3) 	(9) 	(80)
GOODWILL AT SEPTEMBER 30, 2026 	$ 	14,045 $ 	12,867 $ 	7,864 $ 	1,835 $ 	4,586 $ 	41,197
Goodwill decreased from June 30, 2026, primarily due to currency translation.
(1)
(1)
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 9 of 84 --

8 The Procter & Gamble Company
Identifiable intangible assets at September 30, 2026, were comprised of:
Gross Carrying Amount 	Accumulated Amortization
Intangible assets with determinable lives 	$ 	9,151 	$ 	(7,319)
Intangible assets with indefinite lives 	19,527 	—
Total identifiable intangible assets 	$ 	28,678 	$ 	(7,319)
Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives primarily
consist of brands. The amortization expense of determinable-lived intangible assets for the three months ended September 30, 2026 and 2025, was $75 and
$79, respectively.
Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment. We use the income method to estimate the fair
value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. When appropriate, the market approach,
which leverages comparable company revenue and earnings multiples, is weighted with the income approach to estimate fair value. If the resulting fair value is
less than the asset's carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets
occurs during the three months ended December 31. Other than our Gillette indefinite-lived intangible asset, our goodwill reporting units and indefinite-lived
intangible assets have fair values that significantly exceed their underlying carrying values.
Based on our impairment testing performed during the three months ended December 31, 2025, the Gillette indefinite-lived intangible asset's fair value exceeds
its carrying value by greater than 10%. As of September 30, 2026, the carrying value of the Gillette indefinite-lived intangible asset was $12.8 billion. While
we have concluded that no triggering event has occurred during the quarter ended September 30, 2026, the Gillette indefinite-lived intangible asset is
susceptible to impairment risk. Adverse changes in the business or in the macroeconomic environment, including foreign currency devaluation, increasing
global inflation or market contraction from an economic recession, could reduce the underlying cash flows used to estimate the fair value of the Gillette
indefinite-lived intangible asset and trigger an impairment charge.
The most significant assumptions utilized in the determination of the estimated fair value of the Gillette indefinite-lived intangible asset are the net sales
growth rates (including residual growth rate), discount rate and royalty rate.
Net sales growth rates could be negatively impacted by reductions or changes in demand for our Gillette products, which may be caused by, among other
things: changes in the use and frequency of grooming products, shifts in demand away from one or more of our higher priced products to lower priced products
or potential supply chain constraints. In addition, relative global and country/regional macroeconomic factors could result in additional and prolonged
devaluation of other countries' currencies relative to the U.S. dollar. The residual growth rate represents the expected rate at which the Gillette brand is
expected to grow beyond the shorter-term business planning period. The residual growth rate utilized in our fair value estimates is consistent with the brand
operating plans and approximates expected long-term category market growth rates. The residual growth rate depends on overall market growth rates, the
competitive environment, inflation, relative currency exchange rates and business activities that impact market share. As a result, the residual growth rate could
be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the U.S. dollar or an increased
competitive environment.
The discount rate is based on a weighted average cost of capital that is likely to be expected by a market participant, including consideration of both debt and
equity components of the capital structure. Our discount rate may be impacted by adverse changes in the macroeconomic environment, volatility in the equity
and debt markets or other country specific factors, such as further devaluation of currencies against the U.S. dollar. Spot rates as of the fair value measurement
date are utilized in our fair value estimates for cash flows outside the U.S.
The royalty rate used to determine the estimated fair value for the Gillette indefinite-lived intangible asset is driven by historical and estimated future
profitability of the underlying Gillette business. The royalty rate may be impacted by significant adverse changes in long-term operating margins.
We performed a sensitivity analysis for the Gillette indefinite-lived intangible asset as part of our annual impairment testing during the three months ended
December 31, 2025, utilizing reasonably possible changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty rate
to demonstrate the potential impacts to estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point
increase in the discount rate, a 25 basis-point decrease in our short-term and residual growth rates or a 50 basis-point decrease in our royalty rate.
Approximate Percent Change in Estimated Fair Value
+25 bps Discount Rate 	-25 bps Growth Rates 	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset 	(5)% 	(5)% 	(4)%
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 10 of 84 --

The Procter & Gamble Company 9
4. Earnings Per Share
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted
average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing Net earnings attributable
to Procter & Gamble by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of
stock options and other unvested share-based awards based on the treasury stock method and the assumed conversion of preferred stock.
Net earnings per common share were calculated as follows:
CONSOLIDATED AMOUNTS 	Three Months Ended September 30
2026 	2025
Net earnings attributable to P&G (Diluted) 	$ 	4,731 $ 	4,750
Less: Preferred dividends 	72 	73
Net earnings attributable to P&G available to common shareholders (Basic) 	$ 	4,658 $ 	4,677
SHARES IN MILLIONS
Basic weighted average common shares outstanding 	2,323.7 	2,342.1
Add effect of dilutive securities:
Stock options and other unvested share-based awards 	17.0 	25.3
Convertible preferred shares 	66.6 	69.4
Diluted weighted average common shares outstanding 	2,407.2 	2,436.8
NET EARNINGS PER COMMON SHARE
Basic 	$ 	2.00 $ 	2.00
Diluted 	$ 	1.97 $ 	1.95
For the three months ended September 30, 2026 and 2025, the weighted average of stock options that were antidilutive and not included in the diluted net earnings per share
calculation were 22 million and 11 million, respectively.
An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026.
5. Risk Management Activities and Fair Value Measurements
As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and
commodity prices. There have been no significant changes in our risk management policies or activities during the three months ended September 30, 2026.
The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. There was no
significant activity within the Level 3 assets and liabilities during the periods presented.
Cash equivalents were $13.7 billion and $8.7 billion as of September 30, 2026 and June 30, 2026, respectively, and are classified as Level 1 within the fair
value hierarchy. The Company had no other material investments in debt or equity securities during the periods presented.
The fair value of long-term debt was $26.7 billion and $28.3 billion as of September 30, 2026 and June 30, 2026, respectively. This includes the current portion
of long-term debt instruments ($6.6 billion and $6.5 billion as of September 30, 2026 and June 30, 2026, respectively). All long-term debt is recorded at
amortized cost but is measured at fair value for disclosure purposes. Long-term debt designated in a fair value hedging relationship is adjusted for the change in
fair value attributable to the designated hedged risk. We consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on
quoted market prices for identical or similar instruments.
(1)
(2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 11 of 84 --

10 The Procter & Gamble Company
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of September 30, 2026 and June 30, 2026, are as follows:
Notional Amount 	Fair Value Asset 	Fair Value (Liability)
September 30, 2026 June 30, 2026 September 30, 2026 June 30, 2026 September 30, 2026 June 30, 2026
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	5,223 $ 	5,241 $ 	— $ 	— $ 	(315) $ 	(221)
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	12,219 $ 	13,587 $ 	218 $ 	170 $ 	(106) $ 	(173)
TOTAL DERIVATIVES DESIGNATED IN
HEDGING RELATIONSHIPS 	$ 	17,442 $ 	18,828 $ 	218 $ 	170 $ 	(421) $ 	(394)
DERIVATIVES NOT DESIGNATED IN HEDGING RELATIONSHIPS
Foreign currency contracts 	$ 	4,639 $ 	4,146 $ 	5 $ 	6 $ 	(22) $ 	(7)
TOTAL DERIVATIVES AT FAIR VALUE 	$ 	22,081 $ 	22,975 $ 	223 $ 	176 $ 	(442) $ 	(401)
The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying
amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the
fair value adjustment, was $4.9 billion and $5.0 billion as of September 30, 2026 and June 30, 2026, respectively. In addition to the foreign currency derivative
contracts designated in net investment hedging relationships, certain of our foreign currency denominated debt instruments are designated in net investment
hedging relationships. The carrying value of those debt instruments designated in net investment hedging relationships, which includes the adjustment for the
foreign currency transaction gain or loss on those instruments, was $10.6 billion and $12.0 billion as of September 30, 2026 and June 30, 2026, respectively.
The decrease in the notional balance of derivative instruments and debt designated in net investment hedging relationships was primarily driven by maturities,
consistent with the Company's ongoing management of its hedge portfolio.
Derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. Derivative liabilities are presented in Accrued and other
liabilities or Other noncurrent liabilities. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of
Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value
hierarchy.
Certain of the Company's financial instruments used in hedging transactions are governed by industry standard netting and collateral agreements with
counterparties. If the Company's credit rating were to fall below the levels stipulated in the agreements, the counterparties could demand either collateralization
or termination of the arrangements. The aggregate fair value of the instruments covered by these contractual features that are in a liability position was $279
and $260 as of September 30, 2026 and June 30, 2026, respectively. The Company has not been required to post collateral as a result of these contractual
features.
Before tax gains/(losses) on our financial instruments in hedging relationships are categorized as follows:
Amount of Gain/(Loss) Recognized in OCI on
Derivatives
Three Months Ended September 30
2026 	2025
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	(6) $ 	14
For the derivatives in net investment hedging relationships, the amount of gain/(loss) excluded from effectiveness testing, which was recognized in Interest expense, was $59
and $71 for the three months ended September 30, 2026 and 2025, respectively.
In addition to the foreign currency derivative contracts designated in net investment hedging relationships, certain of our foreign currency denominated debt instruments are
designated in net investment hedging relationships. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was
$28 and $30 for the three months ended September 30, 2026 and 2025, respectively.
(1) (2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 12 of 84 --

The Procter & Gamble Company 11
Amount of Gain/(Loss) Recognized in Earnings
Three Months Ended September 30
2026 	2025
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	(94) $ 	6
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	(15) $ 	(6)
The gains/(losses) on the derivatives in fair value hedging relationships are fully offset by the mark-to-market impact of the related exposure. These are both
recognized in Interest expense. The gains/(losses) on derivatives not designated as hedging instruments are substantially offset by the currency mark-to-market
of the related exposure. These are both recognized in Selling, general and administrative expense (SG&A).
6. Commitments and Contingencies
Litigation
We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust
and trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While
considerable uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially
affect our financial position, results of operations or cash flows.
We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the
environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of
environmental remediation will materially affect our financial position, results of operations or cash flows.
Income Tax Uncertainties
The Company is present in approximately 65 countries and over 140 taxable jurisdictions and, at any point in time, has 30–40 jurisdictional audits underway at
various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and
may not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis
and are adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations.
Such adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2013 and forward. We are generally not able to reliably
estimate the timing and ultimate settlement amounts until the close of an audit.
Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2026.
7. Supplemental Information
Share-Based Compensation and Postretirement Benefits
The following table provides a summary of our share-based compensation expense and postretirement benefit impacts:
Three Months Ended September 30
2026 	2025
Share-based compensation expense 	$ 	98 $ 	121
Net periodic benefit cost for pension benefits 	12 	41
Net periodic benefit (credit) for other retiree benefits 	(142) 	(153)
Supplier Finance Programs
The Company has an ongoing program to negotiate extended payment terms with its suppliers consistent with market practices. The Company also supports a
Supply Chain Finance program (“SCF”) with several global financial institutions. Our payment terms for suppliers under this program generally range from 60
to 180 days. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable in our Consolidated Balance Sheets, and
the associated payments are included in operating activities within our Consolidated Statements of Cash Flows. The amount due to suppliers participating in
SCF and included in Accounts payable was approximately $6.5 billion and $6.2 billion as of September 30, 2026 and June 30, 2026, respectively.
Restructuring Program
The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including
manufacturing and workforce optimization. Before tax costs incurred under the ongoing program have
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 13 of 84 --

12 The Procter & Gamble Company
generally ranged from $250 to $500 annually. Consistent with our historical policies for restructuring-type activities, the restructuring program charges will be
funded by and included within Corporate for management and segment reporting.
In June 2025, the Company announced a portfolio and productivity plan to streamline its portfolio and organization to improve its cost structure and
competitiveness. The Company expects to incur approximately $2.0 billion in before-tax restructuring costs over two years. The restructuring activities will be
executed across the Sector Business Units as well as the Enterprise Markets, Corporate Functions and Global Business Services. These restructuring activities
include a plan for a reduction of up to 7,000 non-manufacturing overhead personnel by the end of fiscal 2027. In addition, the plan includes brand and market
exits as well as the optimization of the supply chain and other manufacturing processes. Costs incurred under the plan will consist primarily of costs to separate
employees and asset-related costs to exit facilities.
In fiscal 2026, the Company incurred total before tax restructuring charges of $1.2 billion, including $606 in Costs of products sold, $460 in SG&A and $165
in Other non-operating income/(expense), net.
For the three months ended September 30, 2026, the Company incurred total before tax restructuring charges of $192, including $106 in Costs of products sold,
$82 in SG&A and $4 in Other non-operating income/(expense), net.
The following table presents restructuring activity for the three months ended September 30, 2026:
Separations 	Asset Related Costs 	Other 	Total
RESERVE JUNE 30, 2026 	$ 	229 $ 	— $ 	107 $ 	336
Costs incurred for the three months ended September 30, 2026 	86 	73 	33 	192
Costs paid/settled for the three months ended September 30, 2026 	(97) 	(73) 	(39) 	(208)
RESERVE SEPTEMBER 30, 2026 	$ 	218 $ 	— $ 	102 $ 	320
8. Subsequent Event
On October 1, 2026, the Company completed the acquisition of Thorne, a premium wellness and supplement brand in the vitamins, minerals and supplements
category for $3.9 billion in an all-cash transaction. Thorne primarily sells in North America and will be part of our Personal Health Care operating segment.
The initial accounting and determination of fair value for the acquired assets and liabilities is not yet complete; the preliminary allocation of purchase prices
will be finalized during the three months ending December 31, 2026. The primary assets acquired are an indefinite-lived brand intangible asset and goodwill.
The results of Thorne, which are not material to the Company, will be reported in our Consolidated financial statements beginning with the three months
ending December 31, 2026.
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives
and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-
looking statements may appear throughout this report, including without limitation, in the following sections: “Management's Discussion and Analysis,” “Risk
Factors” and “Notes 3, 6 and 7 to the Consolidated Financial Statements.” These forward-looking statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,”
“will likely result” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and
uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to
update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial
risks, including foreign currency fluctuations, changes in global interest rates and rate differentials, currency exchange or pricing controls and tariffs; (2) the
ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash
flow to allow the Company to effect the expected share repurchases and dividend payments; (3) the ability to successfully manage uncertainties related to
changing political and geopolitical conditions and potential implications such as exchange rate fluctuations, market contraction, boycotts, variability and
unpredictability in trade relations, sanctions, tariffs or other trade controls; (4) the ability to manage disruptions in credit markets or to our banking partners or
changes to our credit rating; (5) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole
supplier and sole manufacturing plant arrangements) and to manage disruption of business due to various factors, including ones outside of our control, such as
natural disasters, conflicts or acts of war, terrorism or disease outbreaks; (6) the ability to successfully manage cost fluctuations and pressures, including prices
of commodities and raw materials and costs of labor, transportation, energy, pensions and healthcare; (7) the ability to compete with our local and global
competitors in new and existing sales channels,
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 14 of 84 --

The Procter & Gamble Company 13
including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products; (8) the ability to manage and
maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including
concerns about safety, quality, ingredients, efficacy, packaging content, cyber incidents, supply chain practices, social or environmental practices or similar
matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party relationships,
such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and
third-party information and operational technology systems, networks and services and maintain the security and functionality of such systems, networks and
services and the data contained therein; (12) the ability to successfully manage demand, supply and operational challenges; (13) the ability to stay on the
leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits, evolving and more
fragmented digital marketing and selling platform requirements and technological advances attained by, and patents granted to, competitors; (14) the ability to
successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and
financial objectives, without impacting the delivery of base business objectives; (15) the ability to successfully achieve productivity improvements and cost
savings and manage ongoing organizational changes while successfully identifying, developing and retaining key employees, including in key growth markets
where the availability of skilled or experienced employees may be limited; (16) the ability to successfully manage current and expanding regulatory and legal
requirements and matters (including, without limitation, those laws, regulations, policies and related interpretations involving product liability, product and
packaging composition, manufacturing processes, intellectual property, labor and employment, antitrust, privacy, cybersecurity, data protection and data
transfers, artificial intelligence, tax, the environment, due diligence, risk oversight, accounting and financial reporting) and to resolve new and pending matters
within current estimates; (17) the ability to manage changes in applicable tax laws and regulations; and (18) the ability to continue delivering progress towards
our environmental sustainability ambitions. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from
those projected herein is included in the section titled "Economic Conditions and Uncertainties" and the section titled "Risk Factors" (Part II, Item 1A) of this
Form 10-Q.
Purpose, Approach and Non-GAAP Measures
The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of
operations and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in
conjunction with, our Consolidated Financial Statements and accompanying Notes.
The MD&A is organized in the following sections:
• Overview
• Recent Developments
• Summary of Results – Three Months Ended September 30, 2026
• Economic Conditions and Uncertainties
• Results of Operations – Three Months Ended September 30, 2026
• Segment Results – Three Months Ended September 30, 2026
• Liquidity and Capital Resources
• Measures Not Defined by U.S. GAAP
Throughout the MD&A we refer to measures used by management to evaluate performance, including unit volume growth, net sales, net earnings, diluted net
earnings per common share (diluted EPS) and operating cash flow. We also refer to a number of financial measures that are not defined under U.S. GAAP,
consisting of organic sales growth, Core earnings per share (Core EPS), free cash flow and free cash flow productivity. The explanation at the end of the
MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to the most
directly comparable U.S. GAAP measure.
Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the
availability and comparability of share and consumption information. References to market share and consumption in the MD&A are based on a combination
of vendor-purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent the
percentage of sales of our products in dollar terms on a constant currency basis relative to all product sales in the category. The Company measures quarter and
fiscal year to date market share through the most recent period for which market share data is available, which typically reflects a lag time of one or two
months as compared to the end of the reporting period. Management also uses unit volume growth to evaluate drivers of changes in net sales. Organic volume
growth reflects year-over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items, if applicable, and is
used to explain changes in organic sales. In the presentation of data in tables or other charts, certain columns and rows may not add due to rounding.

-- 15 of 84 --

14 The Procter & Gamble Company
OVERVIEW
P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to
our consumers around the world. Our products are sold in about 180 countries and territories, primarily through mass merchandisers, e-commerce (including
social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores (including
airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to individual consumers. We have
on-the-ground operations in approximately 65 countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our
products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we
compete are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We believe we are well positioned in the
industry segments and markets in which we operate, often holding a leadership or significant market share position.
The table below lists our reportable segments, including the product categories and brand composition within each segment.
Reportable Segments 	Product Categories (Sub-Categories) 	Major Brands
Beauty
Hair Care (Conditioners, Shampoos, Styling Aids, Treatments) 	Head & Shoulders, Herbal
Essences, Pantene, Rejoice
Personal Care (Antiperspirants and Deodorants, Personal Cleansing) 	Native, Old Spice, Safeguard,
Secret
Skin Care (Facial Moisturizers, Cleaners and Treatments) 	Olay, SK-II
Grooming Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and
Post-Shave Products, Other Grooming) 	Braun, Gillette, Venus
Health Care
Oral Care (Toothbrushes, Toothpastes, Other Oral Care) 	Crest, Oral-B
Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care) Metamucil, Neurobion, Pepto-
Bismol, Vicks
Fabric & Home Care
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents) 	Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze,
Mr. Clean, Swiffer
Habitat Care (Pest Prevention, Outdoor Care) 	Spruce, Zevo
Baby, Feminine & Family Care
Baby Care (Baby Wipes, Taped Diapers and Pants) 	Luvs, Pampers
Feminine Care (Adult Incontinence, Menstrual Care) 	Always, Always Discreet,
Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) 	Bounty, Charmin, Puffs
Throughout the MD&A, we reference business results by region, which are comprised of North America, Europe, Greater China, Latin America, Asia Pacific
and India, Middle East, Türkiye and Africa (IMETA).
The following table provides the percentage of net sales and net earnings by reportable business segment (excluding Corporate) for the three months ended
September 30, 2026:
Three Months Ended September 30, 2026
Net Sales 	Net Earnings
Beauty 	19 % 	18 %
Grooming 	8 % 	10 %
Health Care 	14 % 	16 %
Fabric & Home Care 	36 % 	34 %
Baby, Feminine & Family Care 	23 % 	22 %
Total Company 	100 % 	100 %
RECENT DEVELOPMENTS
Focused Portfolio, Supply Chain and Productivity Plan
In June 2025, the Company announced a portfolio and productivity plan to streamline its portfolio and organization to improve its cost structure and
competitiveness. The Company expects to incur approximately $2.0 billion in before-tax restructuring

-- 16 of 84 --

The Procter & Gamble Company 15
costs over a two-year period. The Company incurred over half of the costs under this plan in fiscal 2026, with the remainder expected to be incurred in fiscal
2027. The restructuring activities are being executed across the Sector Business Units as well as the Enterprise Markets, Corporate Functions and Global
Business Services. These restructuring activities include a plan for a reduction of up to 7,000 non-manufacturing overhead personnel by the end of fiscal 2027.
Consistent with our historical policies for ongoing restructuring-type activities, resulting charges were funded by and included within Corporate for segment
reporting. Restructuring charges above the normal ongoing level of restructuring costs are reported as non-core charges. For more details on the restructuring
program, refer to Note 7 to the Consolidated Financial Statements.
Thorne Acquisition
On October 1, 2026, the Company completed the acquisition of Thorne, a premium wellness and supplement brand in the vitamins, minerals and supplements
category for $3.9 billion in an all-cash transaction. Thorne primarily sells in North America and will be part of our Personal Health Care operating segment.
The results of Thorne, which are not material to the Company, will be reported in our Consolidated financial statements beginning with the three months
ending December 31, 2026.
SUMMARY OF RESULTS – Three Months Ended September 30, 2026
The following are highlights of results for the three months ended September 30, 2026, versus the three months ended September 30, 2025:
• Net sales were $23.3 billion, an increase of $890 million, or 4.0%, versus the prior year period. Net sales increased mid-single digits in Beauty, Fabric &
Home Care and Grooming and low single digits in Health Care and Baby, Feminine & Family Care. Organic sales, which exclude the impacts of
acquisitions and divestitures and foreign exchange, increased 4.0% versus the prior year period. Organic sales increased mid-single digits in Beauty, Fabric
& Home Care and Grooming and low single digits in Baby, Feminine & Family Care and Health Care.
• Diluted EPS increased 1% to $1.97. Core EPS, which represents diluted EPS excluding charges for incremental restructuring, increased 1% to $2.00.
• Operating cash flow was $5.8 billion. Free cash flow, which is defined as operating cash flow less capital expenditures, was $4.4 billion. Free cash flow
productivity, which is defined as free cash flow as a percentage of net earnings, was 93%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
Global Economic Conditions. Our products are sold in numerous countries worldwide, with more than half our sales generated outside the United States. Our
largest international markets are Greater China, the United Kingdom, Canada, Japan and Germany and collectively comprised approximately 21% of our net
sales in fiscal 2026. As a result, we are exposed to global macroeconomic factors, geopolitical tensions and government policies. We are exposed to various
risks due to economic, political and social instabilities, market volatility, natural disasters, debt and credit issues, currency controls, new or increased tariffs,
foreign exchange, the availability and cost of materials and interest rate changes. These risks can negatively impact our net sales, net earnings and cash flows.
For example, we are exposed to risks due to the conflict in the Middle East and the ongoing war between Russia and Ukraine. Our Russia business accounted
for 1% of consolidated net sales, net earnings and net assets as of June 30, 2026.
Foreign Exchange. We have significant exposure to exchange rate fluctuations, both due to translation and transaction exposures. Translation exposures arise
from measuring income statements of foreign subsidiaries with functional currencies other than the U.S. dollar. Transaction exposures involve impacts from 1)
input costs that are denominated in currencies other than the local reporting currency and 2) revaluation of working capital balances denominated in currencies
other than the functional currency. We have experienced significant foreign exchange impacts in the past due to the weakening of certain foreign currencies
versus the U.S. dollar, which have negatively impacted net sales, net earnings and cash flows. In response to the devaluation of foreign currencies (including
those deemed highly inflationary), any lags or inability (due to government restrictions) to implement price increases or the negative impacts of such actions on
product consumption may lead to a decline in our net sales, net earnings and cash flows.
Commodities and Supply Chain. Our costs are subject to fluctuations due to changes in commodity and input material prices, transportation costs,
inflationary impacts and productivity efforts. We have significant exposures to certain commodities and input materials, in particular certain oil-derived
materials like resins and paper-based materials like pulp. Volatility in the market price of commodities and input materials directly affects our costs.
Disruptions in manufacturing, supply and distribution operations can lead to increased costs. Legal or regulatory requirements and sustainability initiatives may
result in increased costs. We strive to implement, achieve and sustain cost improvement plans, including supply chain optimization and general overhead and
workforce optimization. Increased pricing in response to certain inflationary or cost increases may also offset portions of the cost impacts; however, such price
increases may negatively impact product consumption. If we are unable to manage cost impacts through pricing actions and consistent productivity
improvements, it may negatively impact our net sales, net earnings and cash flows.
Government Policies. We are exposed to changes in U.S. and foreign government legislative, regulatory or enforcement policies that can have a negative
impact on net sales, net earnings and cash flows. These include tax policy changes (both U.S.

-- 17 of 84 --

16 The Procter & Gamble Company
and foreign), including those resulting from the current work being led by the OECD/G20 Inclusive Framework focused on "Addressing the Challenges of the
Digitalization of the Economy”. Government controls such as currency exchanges, pricing and import authorizations as well as government policies related to
environmental and climate change matters and changes to international trade agreements, including tariffs, can also impact our financial performance.
For additional information on risk factors that could impact our business results, please refer to Risk Factors in Part I, Item 1A of the Company's Form 10-K for
the fiscal year ended June 30, 2026.
RESULTS OF OPERATIONS – Three Months Ended September 30, 2026
The following discussion provides a review of results for the three months ended September 30, 2026, versus the three months ended September 30, 2025.
Three Months Ended September 30
Amounts in millions, except per share amounts 	2026 	2025 	% Chg
Net sales 	$ 	23,276 $ 	22,386 	4%
Operating income 	5,937 	5,856 	1%
Earnings before income taxes 	6,023 	6,034 	—%
Net earnings 	4,757 	4,781 	(1)%
Net earnings attributable to Procter & Gamble 	4,731 	4,750 	—%
Diluted net earnings per common share 	1.97 	1.95 	1%
Core net earnings per common share 	2.00 	1.99 	1%
Three Months Ended September 30
COMPARISONS AS A PERCENTAGE OF NET SALES 	2026 	2025 	Basis Pt Chg
Gross margin 	49.8 % 	51.4 % 	(160)
Selling, general & administrative expense 	24.3 % 	25.2 % 	(90)
Operating income 	25.5 % 	26.2 % 	(70)
Earnings before income taxes 	25.9 % 	27.0 % 	(110)
Net earnings 	20.4 % 	21.4 % 	(100)
Net earnings attributable to Procter & Gamble 	20.3 % 	21.2 % 	(90)
Net Sales
Net sales for the quarter increased 4.0% to $23.3 billion. The increase in net sales was due to a unit volume increase of 2.4%, favorable geographic mix of
1.1% and higher pricing of 0.4%. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales also increased 4.0%.
The following table summarizes key drivers of the change in net sales by reportable segment:
Net Sales Change Drivers 2026 vs. 2025 (Three Months Ended September 30)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange 	Price 	Mix
Acquisitions &
Divestitures
Net Sales
Growth
Beauty 	2.2 % 	2.2 % 	1.1 % 	0.7 % 	2.5 % 	— % 	6.4 %
Grooming 	(0.4) % 	(0.4) % 	(0.4) % 	3.5 % 	1.5 % 	(0.1) % 	4.0 %
Health Care 	(2.9) % 	(2.9) % 	0.4 % 	2.8 % 	2.8 % 	(0.1) % 	3.1 %
Fabric & Home Care 	4.3 % 	4.3 % 	(0.6) % 	(0.3) % 	0.8 % 	— % 	4.2 %
Baby, Feminine & Family Care 	2.3 % 	2.3 % 	(0.1) % 	(1.2) % 	1.8 % 	— % 	2.9 %
Total Company 	2.4 % 	2.4 % 	— % 	0.4 % 	1.1 % 	— % 	4.0 %
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Acquisitions and Divestitures excluding the volume impact.
Operating Costs
Gross margin decreased 160 basis points to 49.8% of net sales for the quarter. The decrease in gross margin was due to:
• 140 basis points of higher commodity costs,
• 140 basis points of product and packaging investments,
• 50 basis points of decline from unfavorable product mix,
(1)
(2)
(1)
(2)

-- 18 of 84 --

The Procter & Gamble Company 17
• 10 basis points of higher restructuring costs and
• 10 basis points of other items and rounding.
These impacts were partially offset by:
• 120 basis points of manufacturing productivity savings,
• 50 basis points of due to lower tariff costs and recognized recoveries and
• 20 basis points of increase due to higher pricing.
Total SG&A spending was unchanged versus the prior year period at $5.7 billion as increased marketing spending was offset by a decline in overhead costs.
SG&A as a percentage of net sales decreased 90 basis points to 24.3% due primarily to a decrease in overhead costs as a percentage of net sales and a decrease
in marketing spending as a percentage of net sales. Overhead costs as a percentage of net sales decreased 70 basis points driven by productivity savings and the
positive scale impacts of the net sales increase, partially offset by wage inflation. Marketing spending as a percentage of net sales decreased 20 basis points
driven by the positive scale impacts of the net sales increase and productivity savings, partially offset by an increase in marketing spending. Productivity-driven
cost savings delivered 130 basis points of benefit to SG&A as a percentage of net sales.
Operating income increased 1% to $5.9 billion as the increase in net sales was partially offset by a decrease in gross margin, the components of which are
described above. Operating margin decreased 70 basis points to 25.5% versus the prior year period due primarily to the decrease in gross margin, partially
offset by productivity-driven cost savings.
Non-Operating Expenses and Income
Interest expense was $223 million for the quarter, an increase of $26 million versus the prior year period. Interest income was $102 million for the quarter, a
decrease of $6 million versus the prior year period. Other non-operating income/(expense), net was $207 million, a decrease of $61 million versus the prior
year period.
Income Taxes
The effective income tax rate for the three months ended September 30, 2026, was 21.0%, compared to 20.8% for the three months ended September 30, 2025.
The increase in effective tax rate was primarily driven by discrete impacts related to uncertain tax positions, partially offset by favorable geographic mix
impacts.
Net Earnings
Net earnings were $4.8 billion, a decrease of $24 million, or 1%, versus the prior year period, the details of which are described above. Foreign exchange had a
positive impact of approximately $23 million on net earnings for the quarter, including both transactional and translational impacts from converting earnings
from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble were $4.7 billion, a decrease of $19 million for the quarter. Diluted
EPS increased 1% to $1.97 versus the prior year period. Core EPS, which represents diluted EPS excluding charges for incremental restructuring, increased 1%
to $2.00.
SEGMENT RESULTS – Three Months Ended September 30, 2026
The following discussion provides a review of results by reportable business segment. Analysis of the results for the three months ended September 30, 2026, is
provided based on a comparison to the three months ended September 30, 2025. Certain amounts in the prior year presentation between segments were
reclassified to conform to the current year’s presentation. The primary financial measures used to evaluate segment performance are net sales and net earnings.
The table below provides supplemental information on net sales, earnings before income taxes and net earnings by reportable business segment for the three
months ended September 30, 2026, versus the comparable prior year period (dollar amounts in millions):
Three Months Ended September 30, 2026
Net Sales
% Change
Versus Year Ago
Earnings/(Loss) Before
Income Taxes
% Change
Versus Year Ago 	Net Earnings/(Loss)
% Change
Versus Year Ago
Beauty 	$ 	4,410 	6 % $ 	1,139 	1 % $ 	868 	(1) %
Grooming 	1,889 	4 % 	619 	6 % 	477 	3 %
Health Care 	3,318 	3 % 	1,029 	10 % 	783 	9 %
Fabric & Home Care 	8,205 	4 % 	2,080 	4 % 	1,601 	3 %
Baby, Feminine & Family Care 	5,322 	3 % 	1,390 	(4) % 	1,060 	(4) %
Corporate 	132 	N/A 	(234) 	N/A 	(32) 	N/A
Total Company 	$ 	23,276 	4 % $ 	6,023 	— % $ 	4,757 	(1)%
Beauty
Three months ended September 30, 2026, compared with three months ended September 30, 2025

-- 19 of 84 --

18 The Procter & Gamble Company
Beauty net sales increased 6% to $4.4 billion, driven by favorable product mix of 2%, a unit volume increase of 2%, favorable foreign exchange of 1% and
positive impacts of pricing of 1%. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 5%. Global market share
of the Beauty segment decreased 0.2 points.
• Hair Care net sales increased mid-single digits driven by positive impacts of innovation-based pricing (primarily in North America and Latin America),
favorable product mix, an increase in unit volume and favorable foreign exchange. The volume increase was driven by growth in Europe, Asia Pacific and
Greater China (all due to innovation), partially offset by IMETA (due to go-to-market discontinuations under our restructuring program). Organic sales
increased mid-single digits driven by growth in all regions, led by high single-digit growth in Asia Pacific and Latin America and mid-single-digit growth
in North America, partially offset by low single digit growth in Greater China. Global market share of the Hair Care category was unchanged.
• Personal Care net sales increased high single digits driven by an increase in unit volume, favorable product mix and favorable foreign exchange, partially
offset by lower pricing (due to trade investments). The volume increase was driven by growth in Greater China (due to innovation) and Europe (due to
distribution gains). Organic sales increased mid-single digits driven by more than 20% growth in Europe and mid-single-digit growth in North America
and Greater China. Global market share of the Personal Care category decreased 0.4 points.
• Skin Care net sales increased mid-single digits driven by favorable product mix (due primarily to the increase of the super-premium SK-II brand, which
has higher than category-average selling prices), a unit volume increase and favorable foreign exchange. The volume increase was driven by North
America (due to innovation), partially offset by Greater China (due to competitive activity). Organic sales also increased mid-single digits driven by
double-digit growth in Asia Pacific, partially offset by low single-digit growth in Greater China and North America. Global market share of the Skin Care
category decreased 0.6 points.
Net earnings decreased 1% to $868 million due to a 150 basis-point decline in net earnings margin, partially offset by an increase in net sales. Net earnings
margin decreased due to a decrease in gross margin and an increase in SG&A as a percentage of net sales. The gross margin decline of 90 basis points was
driven by the higher cost of commodities and unfavorable product mix, partially offset by productivity savings. SG&A as a percentage of net sales increased
primarily due to an increase in marketing spending, partially offset by lower overhead spending.
Grooming
Three months ended September 30, 2026, compared with three months ended September 30, 2025
Grooming net sales increased 4% to $1.9 billion driven by innovation-driven pricing of 3% (primarily by North America and IMETA) and favorable product
mix of 1%. Unit volume was unchanged as an increase in Europe (due to innovation) was offset by a decrease in Latin America (due to distribution losses) and
IMETA (due to go-to-market discontinuations under our restructuring program). Excluding the impact of acquisitions and divestitures and foreign exchange,
organic sales increased 5% led by high single-digit growth in Europe and mid-single-digit growth in North America and IMETA, partially offset by a low
single-digit decline in Latin America. Global market share of the Grooming segment increased 0.2 points.
Net earnings increased 3% to $477 million due to an increase in net sales, partially offset by a 30 basis-point decrease in net earnings margin. Net earnings
margin decreased due to an increase in the effective tax rate, partially offset by an increase in gross margin. The gross margin increase of 60 basis points was
primarily driven by higher pricing, recognized tariff recoveries and productivity savings, partially offset by unfavorable product mix. SG&A as a percentage of
net sales was unchanged as the positive scale impacts of the net sales increase and a decrease in overhead spending was offset by an increase in marketing
spending. The higher effective tax rate was driven by unfavorable geographic mix.
Health Care
Three months ended September 30, 2026, compared with three months ended September 30, 2025
Health Care net sales increased 3% to $3.3 billion driven by higher pricing of 3% and favorable product mix of 3%, partially offset by a 3% decrease in unit
volume. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 3%. Global market share of the Health Care
segment was unchanged.
• Oral Care net sales increased low single digits driven by positive impacts of favorable product mix (due to growth of power brushes and premium paste,
which have higher than category-average selling prices) and innovation-based pricing (driven by North America), partially offset by a unit volume decline.
The unit volume decrease was driven by declines in Latin America and Greater China (both due to go-to-market discontinuations under our restructuring
program) and North America (due to competitive activity), partially offset by an increase in Europe (due to distribution gains). Organic sales increased low
single digits driven by a double-digit increase in Europe, partially offset by a high single-digit decrease in Latin America and a low single-digit decrease in
North America. Global market share of the Oral Care category decreased 0.6 points.
• Personal Health Care net sales increased mid-single digits driven by higher pricing (driven by North America and Latin America), favorable product mix
and favorable foreign exchange, partially offset by a unit volume decrease. The unit

-- 20 of 84 --

The Procter & Gamble Company 19
volume decrease was driven by Latin America and North America (both due to lower average incidence of cough and cold). Organic sales increased low
single digits driven by a high single-digit increase in IMETA and mid-single-digit increases in North America and Europe, partially offset by a low single-
digit decrease in Latin America. Global market share of the Personal Health Care category increased 0.5 points.
Net earnings increased 9% to $783 million due to an increase in net sales and a 130 basis-point increase in net earnings margin. Net earnings margin increased
due to a increase in gross margin, partially offset by a increase in SG&A as a percentage of net sales and an increase in the effective tax rate. The gross margin
increase of 200 basis points was driven primarily by higher pricing, recognized tariff recoveries and productivity savings, partially offset by unfavorable
product mix and the higher cost of commodities. SG&A as a percentage of net sales increased due to an increase in marketing spending, partially offset by a
decrease in overhead spending. The higher effective tax rate was driven by unfavorable geographic mix.
Fabric & Home Care
Three months ended September 30, 2026, compared with three months ended September 30, 2025
Fabric & Home Care net sales increased 4% to $8.2 billion driven by a unit volume increase of 4% and favorable geographic mix of 1%, partially offset by
unfavorable foreign exchange of 1%. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 5%. Global market
share of the Fabric & Home Care segment increased 0.3 points.
• Fabric Care net sales increased mid-single digits driven by positive impacts from a unit volume increase and favorable geographic mix, partially offset by
negative impacts from unfavorable foreign exchange. The unit volume increase was driven by an increase in North America, Europe and Latin America
(all due to market growth). Organic sales increased mid-single digits driven by a low teens increase in Latin America and mid-single-digit increases in
North America and Europe. Global market share of the Fabric Care category increased 0.4 points.
• Home Care net sales increased mid-single digits driven by a unit volume increase and favorable product mix, partially offset by unfavorable foreign
exchange. The increase in volume was led by North America (due to distribution gains) and Europe and Asia Pacific (both due to innovation). Organic
sales increased mid-single digits driven by mid-single-digit increases in North America and Europe. Global market share of the Home Care category was
unchanged.
Net earnings increased 3% to $1.6 billion due to an increase in net sales, partially offset by a 20 basis-point decrease in net earnings margin. Net earnings
margin decreased due to a decrease in gross margin, partially offset by a decrease in SG&A as a percentage of net sales. The gross margin decrease of 290 basis
points was driven by the higher cost of commodities, product investments and unfavorable product mix, partially offset by productivity savings. SG&A as a
percentage of net sales decreased due to decreases in marketing spending and overhead spending.
Baby, Feminine & Family Care
Three months ended September 30, 2026, compared with three months ended September 30, 2025
Baby, Feminine & Family Care net sales increased 3% to $5.3 billion driven by a unit volume increase of 2% and favorable product mix of 2%, partially offset
by lower pricing of 1%. Excluding the impacts of foreign exchange and acquisitions and divestitures, organic sales increased 3%. Global market share of the
Baby, Feminine & Family Care segment was unchanged.
• Baby Care net sales increased mid-single digits driven by a unit volume increase and favorable impacts from product mix, partially offset by lower pricing
(primarily in North America). The unit volume increase was driven by increases in Greater China and North America (both due to distribution gains),
partially offset by a decrease in Europe (due to market contraction). Organic sales increased mid-single digits driven by a more than 40% increase in
Greater China and a low teens increase in IMETA, partially offset by a low single-digit increase in North America and a low single-digit decrease in
Europe. Global market share of the Baby Care category increased 0.8 points.
• Feminine Care net sales increased low single digits driven by favorable geographic mix and innovation-based pricing (primarily in North America),
partially offset by a unit volume decrease. The unit volume decrease was driven by declines in Europe (due to competitive activity) and IMETA (due to go-
to-market discontinuations under our restructuring program), partially offset by an increase in North America (due to distribution gains). Organic sales
increased low single digits driven by high single-digit increases in North America and Greater China, partially offset by a mid-single-digit decrease in
Europe. Global market share of the Feminine Care category was unchanged.
• Net sales in Family Care, which is predominantly a North America business, increased low single digits driven by a unit volume increase (due to market
growth), partially offset by lower pricing (due to merchandising investments). Organic sales also increased low single digits. North America market share
of the Family Care category decreased 0.5 points.
Net earnings decreased 4% to $1.1 billion due to a 150 basis-point decrease in net earnings margin, partially offset by an increase in net sales. Net earnings
margin decreased due to a decrease in in gross margin, partially offset by a decrease in SG&A as a percentage of net sales. The gross margin decrease of 220
basis points was primarily due to the higher cost of commodities and merchandising investments, partially offset by the lower cost of tariffs. SG&A as a
percentage of net sales decreased due a reduction in overhead spending, partially offset by an increase in marketing spending.
Corporate

-- 21 of 84 --

20 The Procter & Gamble Company
Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include but are not limited to incidental
businesses managed at the corporate level, gains and losses related to certain divested brands or businesses, impacts from various financing and investing
activities, certain impacts related to employee benefits, asset impairments and restructuring activities including manufacturing and workforce optimization.
Corporate also includes reconciling items to adjust the accounting policies used within the reportable segments to U.S. GAAP. The most notable ongoing
reconciling item is income taxes, which adjusts the blended statutory rates that are reflected in the reportable segments to the overall Company effective tax
rate.
For the three months ended September 30, 2026, Corporate net sales decreased $33 million to $132 million. Corporate net earnings decreased $94 million to a
loss of $32 million for the quarter.
LIQUIDITY & CAPITAL RESOURCES
Operating Activities
Operating cash flow was $5.8 billion fiscal year to date, an increase of $359 million versus the prior year period. Net earnings, adjusted for non-cash items
(depreciation and amortization, share-based compensation expense, deferred income taxes and (gain)/loss on sale of assets), generated $5.8 billion of operating
cash flow. Working capital and other impacts were largely neutral, generating $7 million of cash in the period. Accounts receivable increased, consuming $589
million of cash, driven primarily by sales growth. Days sales outstanding increased by one day. Total inventories increased, consuming $349 million of cash,
driven primarily by increased safety stock levels. Days inventory on hand decreased by two days. Trade payables increased, generating $1.1 billion of cash,
driven primarily by increased supply chain activity, partially offset by decreased marketing support activity. Other impacts consumed additional cash of $204
million primarily driven by a reduction in postretirement benefit and compensation accruals, partially offset by current year income tax accruals in excess of
estimated payments.
Investing Activities
Investing activities used $1.5 billion of cash fiscal year to date primarily driven by capital expenditures.
Financing Activities
Financing activities generated $1.1 billion of net cash fiscal year to date, mainly due to a net debt increase related to the planned acquisition of Thorne. This
was partially offset by dividends to shareholders and treasury stock purchases.
As of September 30, 2026, our current liabilities exceeded current assets by $12.5 billion. We anticipate being able to support our short-term liquidity and
operating needs largely through cash generated from operations. We have strong short- and long-term debt ratings that have enabled and should continue to
enable us to refinance our debt as it becomes due in commercial paper and bond markets. In addition, we have agreements with a diverse group of financial
institutions that, if needed, should provide sufficient funding to meet short-term financing requirements.
MEASURES NOT DEFINED BY U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most
closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e., trends excluding non-recurring
or unusual items) and results and provide a supplemental measure of period-to-period results. The non-GAAP measures described below are used by
management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors, as
they provide supplemental information about business performance and provide investors a view of our business results through the eyes of management.
These measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not
intended to be considered by the user in place of the related GAAP measures but rather as supplemental information to our business results. These non-GAAP
measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted.
Organic sales growth. Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign
exchange from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by
providing sales growth on a consistent basis. This measure is used in assessing the achievement of management goals for at-risk compensation.

-- 22 of 84 --

The Procter & Gamble Company 21
The following tables provide a numerical reconciliation of net sales growth to organic sales growth:
Three Months Ended September 30, 2026 	Net Sales Growth 	Foreign Exchange Impact
Acquisition & Divestiture
Impact 	Organic Sales Growth
Beauty 	6.4 % 	(1.1) % 	— % 	5.4 %
Grooming 	4.0 % 	0.4 % 	0.2 % 	4.5 %
Health Care 	3.1 % 	(0.4) % 	— % 	2.7 %
Fabric & Home Care 	4.2 % 	0.6 % 	— % 	4.8 %
Baby, Feminine & Family Care 	2.9 % 	0.1 % 	— % 	3.0 %
Total Company 	4.0 % 	— % 	— % 	4.0 %
Free cash flow. Free cash flow is defined as operating cash flow less capital spending. Free cash flow represents the cash that the Company is able to generate
after taking into account planned maintenance and asset expansion. We view free cash flow as an important measure because it is one factor used in
determining the amount of cash available for dividends, share repurchases, acquisitions and other discretionary investments.
The following table provides a numerical reconciliation of free cash flow ($ millions):
Three Months Ended September 30, 2026
Operating Cash Flow 	Capital Spending 	Free Cash Flow
$ 	5,767 $ 	(1,366) $ 	4,401
Free cash flow productivity. Free cash flow productivity is defined as the ratio of free cash flow to net earnings. We view free cash flow productivity as a
useful measure to help investors understand P&G’s ability to generate cash. Free cash flow productivity is used by management in making operating decisions,
in allocating financial resources and for budget planning purposes. This measure is also used in assessing the achievement of management goals for at-risk
compensation.
The following table provides a numerical reconciliation of free cash flow productivity ($ millions):
Three Months Ended September 30, 2026
Free Cash Flow 	Net Earnings 	Free Cash Flow Productivity
$ 	4,401 $ 	4,757 	93 %
Core EPS. Core EPS is a measure of the Company's diluted EPS excluding items that are not judged by management to be part of the Company's sustainable
results or trends. Management views this non-GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used
in assessing the achievement of management goals for at-risk compensation. The Core earnings measures included in the following reconciliation tables refer
to the equivalent GAAP measures adjusted as applicable for the following items:
• Incremental restructuring: The Company has historically had an ongoing level of restructuring activities of approximately $250 - $500 million before
tax annually. In June 2025, the Company announced a portfolio and productivity plan to streamline its portfolio and organization to improve its cost
structure and competitiveness. The Company expects to incur approximately $2 billion in before-tax restructuring costs over two years and has
incurred over half of the costs under this plan in fiscal 2026, with the remainder expected to be incurred in fiscal 2027. The adjustments to Core
earnings include the restructuring charges that exceed the normal, recurring level of restructuring charges.
We do not view the above items to be part of our sustainable results, and their exclusion from Core earnings measures provides a more comparable measure of
year-on-year results. This item is also excluded when evaluating senior management in determining their at-risk compensation.

-- 23 of 84 --

22 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Three Months Ended September 30, 2026
Amounts in millions except per share amounts 	As Reported (GAAP) 	Incremental Restructuring
Core
(Non-GAAP)
Cost of products sold 	$ 	11,678 $ 	(44) $ 	11,634
Selling, general and administrative expense 	5,661 	(54) 	5,607
Operating income 	5,937 	98 	6,035
Other non-operating income/(expense), net 	207 	2 	209
Income taxes 	1,267 	20 	1,287
Net earnings 	4,757 	80 	4,837
Less: Net earnings attributable to noncontrolling interests 	26 	2 	28
Net earnings attributable to P&G 	4,731 	77 	4,808
Core EPS
Diluted net earnings per common share 	$ 	1.97 $ 	0.03 $ 	2.00
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
Net earnings attributable to P&G 	— %
Core net earnings attributable to P&G 	(1)%
Diluted net earnings per common share 	1 %
Core EPS 	1 %
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Three Months Ended September 30, 2025
Amounts in millions except per share amounts 	As Reported (GAAP) 	Incremental Restructuring
Core
(Non-GAAP)
Cost of products sold 	$ 	10,887 $ 	(39) $ 	10,848
Selling, general and administrative expense 	5,643 	(77) 	5,566
Operating income 	5,856 	116 	5,972
Other non-operating income/(expense), net 	268 	7 	275
Income taxes 	1,253 	23 	1,276
Net earnings attributable to P&G 	4,750 	100 	4,850
Core EPS
Diluted net earnings per common share 	$ 	1.95 $ 	0.04 $ 	1.99
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the Company’s exposure to market risk since June 30, 2026. Additional information can be found in Note 9, Risk
Management Activities and Fair Value Measurements, of the Company's Form 10-K for the fiscal year ended June 30, 2026.
Item 4. 	Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s Chairman of the Board, President and Chief Executive Officer, Shailesh Jejurikar, and the Company’s Chief Financial Officer, Andre Schulten,
performed an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of
1934 (Exchange Act)) as of the end of the period covered by this report.
Messrs. Jejurikar and Schulten have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be
disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed,
(1)
(1)
(1)
(1)

-- 24 of 84 --

The Procter & Gamble Company 23
summarized and reported within the time periods specified in SEC rules and forms, and (2) accumulated and communicated to our management, including
Messrs. Jejurikar and Schulten, to allow their timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the Company’s fiscal quarter ended September 30, 2026, that have
materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. 	Legal Proceedings
The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including
antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters and
tax. In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State or local law when a governmental
authority is a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold ($1
million or more).
There were no material changes during the quarter ended September 30, 2026, to our disclosure in Part I, Item 3, “Legal Proceedings” of our Form 10-K for the
fiscal year ended June 30, 2026. There were no relevant matters to disclose under this Item for this period.
Item 1A. 	Risk Factors
For information on risk factors, please refer to "Risk Factors" in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended June 30, 2026.
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of
Shares Purchased
Average Price Paid per
Share
Total Number of Shares Purchased as Part
of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares that May Yet
Be Purchased Under Our Share Repurchase
Program
7/01/2026 - 7/31/2026 	2,946,201 	$149.29 	—
8/01/2026 - 8/31/2026 	4,319,833 	144.68 	4,319,833
9/01/2026 - 9/30/2026 	4,271,128 	146.33 	4,271,128
Total 	11,537,162 	$146.47 	8,590,961 	(3)
All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to
satisfy tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third
party and does not repurchase stock in connection with cashless exercises.
Average price paid per share for open market transactions excludes commission.
In accordance with the repurchase program announced on July 29, 2026, the Company reaffirmed in its earnings release on October 22, 2026, that it expects to reduce
outstanding shares through direct share repurchases at a value of approximately $5.0 billion in fiscal year 2027, notwithstanding any purchases under the Company's
compensation and benefit plans. Purchases may be made in the open market and/or private transactions and purchases may be increased, decreased or discontinued at any
time without prior notice. The share repurchases are authorized pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a
combination of operating cash flows and issuance of debt.
Item 5. 	Other Information
During the three months ended September 30, 2026, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule
10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.
Segment Realignment
During the three months ended September 30, 2026, the Company realigned its Fabric & Home Care reporting segment to include Habitat Care, which is now
operating under the Fabric & Home Care leadership team. Previously, the results of the Habitat Care business were reported in the Corporate segment. Certain
amounts in the prior year presentation between segments were reclassified to conform to the current year’s presentation.
The aforementioned changes in Net sales and Net earnings/(loss) for our Fabric & Home Care reportable segment were not material for the years ended June
30, 2026, 2025 and 2024.
(1) 	(2) 	(3)
(3)
(3)
(3)
(1)
(2)
(3)

-- 25 of 84 --

24 The Procter & Gamble Company
The table below presents the results as if the segment changes had been in effect for the noted periods.
Fiscal years ended June 30 	2026 	2025 	2024
Fabric & Home Care
Net sales 	$ 	30,647 $ 	29,878 $ 	29,672
Cost of products sold 	(16,644) 	(15,846) 	(15,708)
Selling, general and administrative expense 	(6,875) 	(6,737) 	(6,808)
Other segment items 	— 	1 	10
Earnings/(loss) before income taxes 	7,128 	7,296 	7,167
Net earnings/(loss) 	$ 	5,508 $ 	5,722 $ 	5,554
Corporate
Net sales 	$ 	587 $ 	534 $ 	423
Cost of products sold 	(1,179) 	(922) 	(909)
Selling, general and administrative expense 	(530) 	(215) 	(607)
Other segment items 	623 	(294) 	(1,156)
Earnings/(loss) before income taxes 	(499) 	(898) 	(2,249)
Net earnings/(loss) 	$ 	100 $ 	(402) $ 	(1,298)
Other segment items for each reportable segment includes interest expense, interest income and certain other non-operating income/(expense).
(1)
(1)
(1)

-- 26 of 84 --

The Procter & Gamble Company 25
Item 6. 	Exhibits
3.1 Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the
Board of Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June
30, 2016)
3.2 Regulations (as approved by the Board of Directors on December 13, 2022, pursuant to authority granted by shareholders at the annual
meeting on October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company’s Current Report on Form 8-K filed
December 13, 2022)
4.1 Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (Incorporated
by reference to Exhibit (4-1) of the Company's Annual Report on Form 10-K for the year ended June 30, 2015)
10.1 Performance Stock Program Summary*+
10.2 Short Term Achievement Reward Program*+
10.3 Form of STAR Stock Option Award Agreement*+
10.4 Form of PSU Award Agreement*+
10.5 Form of LTIP RSU Agreement*+
10.6 Form of LTIP Stock Option Award Agreement*+
31.1 Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2 Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1 Section 1350 Certifications – Chief Executive Officer +
32.2 Section 1350 Certifications – Chief Financial Officer +
101.SCH 	Inline XBRL Taxonomy Extension Schema Document
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF 	Inline XBRL Taxonomy Definition Linkbase Document
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
+ Filed herewith
Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
THE PROCTER & GAMBLE COMPANY
October 22, 2026 	/s/ MATTHEW W. JANZARUK
Date 	(Matthew W. Janzaruk)
Senior Vice President - Chief Accounting Officer
(Principal Accounting Officer)
(1)
(1)
(1)
(1)
(1)
(1)

-- 27 of 84 --

Exhibit 10.1
Performance Stock Program Summary

-- 28 of 84 --

PERFORMANCE STOCK PROGRAM SUMMARY
(Effective September 13, 2026)
The Performance Stock Program (“PSP”) is a part of The Procter & Gamble Company’s (the “Company”) long-term incentive (“LTI”)
compensation and is designed to provide additional focus on key Company measures for top executives with senior management
responsibility for total Company results. Awards granted under the PSP (“PSP Awards”) are made pursuant to authority delegated
to the Compensation & Leadership Development Committee (the “C&LD Committee”) by the Board of Directors for determining
compensation for the Company’s principal officers and for making awards under the Procter & Gamble 2025 Stock and Incentive
Compensation Plan (the “2025 Plan”) or any successor stock plan approved in accordance with applicable listing standards.
I. ELIGIBILITY
The Chairman of the Board and/or Chief Executive Officer and those active executives at Band 6 or above as of June 1 prior to the
grant date and recommended by management are eligible to participate (“Participants”). In special circumstances such as for
acquisitions or experienced hires, the CHRO may authorize participation for Band 6 or above employees who are not active as of
June 1 but are active employees as of the grant date.
II. OVERVIEW
A significant portion of the Band 6 and above compensation is delivered through two long-term incentive programs tied to Company
performance: PSP and the Long-term Incentive Program.
Total long-term incentive compensation targets are based on relevant competitive market data considering the median total long-
term compensation of comparable positions, regressed for revenue size. The C&LD Committee establishes the Peer Group and
sets compensation targets for all Principal Officers, including the CEO. The CEO approves compensation targets for non-Principal
Officers (generally Band 6 managers).
The C&LD Committee determines the long-term incentive award for the CEO. The CEO recommends all other Principal Officer
awards to the C&LD Committee based on benchmarked long-term compensation targets, adjusted for business results and
individual contributions attributable to each executive and including that individual’s leadership skills. The C&LD Committee retains
full authority to accept, modify, or reject these recommendations. The CEO approves awards for participants who are not Principal
Officers based on long-term compensation targets, business results and individual contributions. Long-term incentive awards can
be up to 50% above or 50% below the benchmarked target. In exceptional cases, no award will be made. After total LTI award size
is determined then approximately half of each Band 7 manager’s long-term compensation is allocated to PSP via an Initial PSU
Grant (as defined below). The remaining portion is a Long-term Incentive Program Grant. Approximately 25% of each Band 6
manager’s total LTI is allocated to PSP with the remainder awarded under the Long-term Incentive Program.
PSP rewards Participants for Company performance against certain three-year performance goals in categories established by the
C&LD Committee. The C&LD Committee sets these performance goals for each three-year period that begins on July 1 and ends
on June 30 three years later (“Performance Period”). In the first year of each Performance Period, the C&LD Committee grants
Performance Stock Units (“PSUs”) to Participants that will vest at the end of the Performance Period based on the Company’s
performance relative to the pre-established performance goals (“Initial PSU Grant”). The number of PSUs that vest at the end of the
Performance Period depends on the Company’s performance against the pre-established performance goals. Vested PSUs,
including dividend equivalents, are converted into shares of the Company’s common stock (“Common Stock”) delivered to the
applicable Participant within 60 days following the end of the Performance
Approved September 13, 2026

-- 29 of 84 --

Period, or such later date as may be elected by the Participant in accordance with Section 409A of the Internal Revenue Code
(“Section 409A”).
III. PERFORMANCE CATEGORIES
The PSP Award is based on the Company’s performance in each of the following categories (each a “Performance Category”) and
weighted as indicated:
• Organic sales growth (percentile rank in the Organic Sales competitive peer group)* – 30%
• Constant currency core before-tax operating profit growth – 20%
• Core earnings per share (EPS) growth – 30%
• Adjusted free cash flow productivity – 20%
Awards will be further adjusted based on the three-year relative total shareholder return (R-TSR) of P&G compared to the Relative
TSR competitive peer group.* A positive R-TSR multiplier will be applied for above-target performance and a negative multiplier for
below target performance. The target thresholds for the multiplier will be approved by the C&LD Committee for each performance
period.
* The Organic Sales competitive peer group and Relative TSR competitive peer group are defined in the PSP Accounting
Guidelines.
Within the first 90 days of each Performance Period, the C&LD Committee sets three-year performance goals (“Performance
Goals”) for each Performance Category for such Performance Period and establishes a sliding scale to measure the Company’s
performance against each Performance Goal in each Performance Category. The C&LD Committee uses the sliding scale to
establish a payout factor between 0% and 200% for each Performance Category (aka “Sales Factor”, “Profit Factor”, “EPS Factor”
and “Cash Flow Factor”, collectively, “Performance Factors”). The final aggregated payout factor (including the R-TSR multiplier)
may not exceed 200%.
In all cases, the C&LD Committee retains the discretion to include or exclude certain of the Performance Categories for purposes of
determining the PSP Award. The C&LD Committee may reduce or eliminate any payment if it determines that such payout is
inconsistent with long-term shareholders’ interests or incongruous with the overall performance of the company.
PSP awards will have the following terms unless otherwise approved by the C&LD Committee.
IV. THE INITIAL PSU GRANT
The C&LD Committee has the sole discretion to establish the target award (“PSP Target”) for each Participant serving as a Principal
Officer. The CEO establishes the PSP Targets for participants who are not Principal Officers. The PSP Target will be a cash amount
and will be the basis for the Initial PSU Grant. The C&LD Committee will make the Initial PSU Grant on the first business day in
October (“Grant Date”) following the beginning of each Performance Period. If the New York Stock Exchange is closed on the day
of the grant, then the C&LD Committee will establish a grant date as soon as practical subsequent to the date previously specified
for such award. The Initial PSU Grant will set forth a target and maximum number of PSUs. The target number of PSUs will be
determined by dividing the PSP Target by the closing price (“Grant Price”) of the Company’s Common Stock on the New York Stock
Exchange as of the close of business on the Grant Date, rounding to the nearest whole unit.
Approved September 13, 2026

-- 30 of 84 --

V. PSU VESTING AND PAYMENT
After the Performance Period is complete, the C&LD Committee will establish the Payout Factors for each of the Performance
Categories based on the Company’s results versus the pre-established Performance Goals. The number of PSUs that vest will be
determined by multiplying the Performance Factors by their respective weightings, summing up the results, then applying the R-
TSR multiplier if applicable. The final result will be rounded up or down to the nearest full percentage. The resulting percentage will
be applied to the number of PSUs in the Initial PSU Grant target, including dividends that would have accumulated since the initial
PSU grant on the vested units. Any resulting fractional share units may be paid as cash, fractional shares, or rounded up to the next
full share based on administrative preference of the Company. The number of PSUs that vest may be equal to, above or below the
Initial PSU Grant target depending on the Company’s performance in the Performance Categories, but in no event more than the
Initial PSU Grant maximum. Vested PSUs are converted into shares of Common Stock delivered to the applicable Participant within
60 days following the end of the Performance Period, or such later date as may be elected by the Participant if applicable and in
accordance with Section 409A.
Participants at Band 7 and above may elect to defer delivery of the Common Stock by electing to receive Restricted Stock Units.
PSP RSUs will have the following terms unless otherwise approved by the Committee at grant:
VESTING AND SETTLEMENT: PSP RSUs will be vested on the grant date with a settlement date at least one year following
the original PSU delivery date (as elected by the Participant), are eligible for dividend equivalents, and can be further deferred in
accordance with Section 409A. These RSUs will be paid on their Original Settlement Date or the Agreed Settlement Date, except in
the case of death. In the case of death (except in France and the UK), payment will be made by the later of the end of the calendar
year or two and a half months following the date of death. For awards granted in France or the UK, the consequences of death are
determined by the local plan supplement, if applicable.
VI. SEPARATION FROM THE COMPANY (Defined terms shall have the meaning designated in the Procter & Gamble 2025 Stock
and Incentive Compensation Plan (“2025 Plan”) or related award documents).
If the Participant’s Termination of Employment occurs for any reason before the Vest Date then the Award will be forfeited unless
one of the conditions listed below is met. If the Participant remains employed through the Vest Date, the Award will paid on the
Settlement Date. For the purposes of the Award, termination of employment will be effective as of the date the Participant is no
longer actively employed and will not be extended by any notice period required under local law. Participants must remain in
compliance with the terms and conditions set forth in the 2025 Plan, including those in Article 6 of the Plan and in the applicable
Award Agreement.
1. Termination on Account of Death. In the event of death, the Award is not forfeited and will become deliverable on the
Settlement Date or Agreed Settlement Date, whichever is applicable.
2. Termination for a Qualified Reason Listed Below. In the event the Participant terminates employment for one of the
qualified reasons listed below, after the Grant Date but within four weeks, the Award will be forfeited. In the event of termination for
one of the qualified reasons listed below, on or after four weeks following the Grant Date, but prior to September 30 of the following
year, the Award will be prorated based on the number of days the Participant remained an employee between the Grant Date and
September 30 of the following year. If the termination for one of the qualified reasons listed below occurs after September 30 of the
following year, the entire Award will be retained. The portion of the Award that is ultimately retained will be delivered on the
Settlement Date in the Award Agreement as long as the Participant remains in compliance
Approved September 13, 2026

-- 31 of 84 --

with the terms of the Plan, the Award Agreement, and the Regulations. Qualified termination reasons are as follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention;
or
• Termination in connection with a divestiture or separation of any of the Company’s businesses.
VII. CHANGE IN CONTROL
Notwithstanding the foregoing, if there is a Change in Control that meets the requirements of a change in control event under
Section 409A, all outstanding PSP Awards will vest and be paid according to Article 17 of the 2025 Plan. If there is a Change in
Control event that does not meet the requirements of a change in control event under Section 409A, all outstanding PSP Awards
will be settled according to the terms and conditions set forth herein, without the application Article 17 of the 2025 Plan. “Change in
Control” shall have the same meaning as defined in the 2025 Plan or any successor stock plan approved in accordance with
applicable listing standards.
VIII. GENERAL TERMS AND CONDITIONS
It shall be understood that the PSP does not give to any officer or employee any contract rights, express or implied, against any
Company for any PSP Award, or for compensation in addition to the salary paid to him or her, or any right to question the action of
the Board of Directors or the C&LD Committee.
Awards to Section 16 Officers are subject to the Dodd-Frank Recoupment Policy as adopted by the C&LD Committee, while awards
to all other Band 7 and above executives are subject to the Senior Executive Recoupment Policy as adopted by the C&LD
Committee.
To the extent applicable, it is intended that the PSP comply with the provisions of Section 409A. The PSP will be administered and
interpreted in a manner consistent with this intent. Neither a Participant nor any of a Participant’s creditors or beneficiaries will have
the right to subject any deferred compensation (within the meaning of Section 409A) payable under the PSP to any anticipation,
alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A,
any deferred compensation (within the meaning of Section 409A) payable to a Participant under the PSP may not be reduced by, or
offset against, any amount owing by a Participant to the Company.
This program document may be amended at any time by the C&LD Committee.
Approved September 13, 2026

-- 32 of 84 --

Exhibit 10-2
Short Term Achievement Reward Program

-- 33 of 84 --

SHORT TERM ACHIEVEMENT REWARD PROGRAM
(Effective August 11, 2026)
The Short-Term Achievement Reward (“STAR”) Program is The Procter & Gamble Company’s (the “Company”) annual bonus
program designed to motivate and reward employees for achieving outstanding short-term business results for the Company and
its subsidiaries. STAR awards are made pursuant to authority delegated to the Compensation & Leadership Development
Committee (the “C&LD Committee”) by the Board of Directors for awarding compensation to the Company’s principal officers and
for making awards under the Procter & Gamble 2025 Stock and Incentive Compensation Plan (the “2025 Plan”) or any successor
stock plan approved in accordance with applicable listing standards.
I. ELIGIBILITY
Employees at Band 1 or above and who worked at least 1 day during the applicable fiscal year are eligible to participate. Eligible
employees who do not work a full schedule (e.g., leaves of absence, disability, and less-than-full-time schedules) in the fiscal year
in which the award is payable may have awards pro-rated.
II. CALCULATION
The individual STAR Award is calculated as follows:
(STAR Target) x [ (Business Unit Performance Factor x 70% weighting) + (Total Company Performance Factor X 30%
weighting) ]
• The STAR Target for each participant is calculated as:
(Base Salary) x (STAR Target percent) where Base Salary at the end of the applicable fiscal year is used to calculate the
STAR award; except in cases where an employee has a reduction in salary during the fiscal year, in which case the salary
would be prorated, or in cases where an employee becomes ineligible for the program during the fiscal year, in which case
base salary as of the end of the STAR eligible level will be used. Base salary may also include certain allowances where the
inclusion of these allowances in base pay is the predominant market practice. The Head of Total Rewards will review and
approve any countries and allowances that will be included in base pay for purposes of the STAR award calculation.
Generally, the STAR Target Percent is dependent on the individual’s position and level (Band) in the organization. The STAR
Target percent for participants at Band 7 or above is set by the C&LD Committee. The STAR Target percent for all other
participants is set by the Chief Executive Officer, with the concurrence of the Chief Human Resources Officer, pursuant to
authority delegated to them by the C&LD Committee. If an individual’s position and/or level changes during a fiscal year, and
that change results in a new STAR Target Percent, the STAR Target Percent is pro-rated according to the amount of time in
each position/level during the fiscal year.
• The Business Unit Performance Factor is weighted at 70% and is based on the fiscal year success for the appropriate STAR
business unit. The STAR business units are defined by the Chief Human Resources Officer and may consist of business
categories, segments, geographies, functions, organizations or a combination of one or more of these items. The STAR
business units will be defined within ninety (90) days of the beginning of the fiscal year but may be adjusted as necessary to
reflect business and/or organizational changes (e.g., reorganization, acquisition, merger, divestiture, etc.). The Business Unit
Performance Factors can range from 0% to 200% with a target of 100%. In general, a committee consisting of at least two of
the Chief Executive Officer, Chief Financial Officer, Chief Human Resources
STAR Program Summary FY 2026-27 – Approved August 11, 2026

-- 34 of 84 --

Officer and/or the Chief Operating Officer (the “STAR Committee”), conducts a comprehensive retrospective assessment of the
fiscal year performance of each STAR business unit against previously established goals and relative to competition for one or
more of the following measures: Operating Total Shareholder Return, After Tax Profit, Free Cash Flow Productivity, Value Share,
Organic Sales, Internal controls, Accounts receivable, Inventory, Organization Head Self-Assessment, and Cross Organization
Assessment. The STAR Committee makes a recommendation of an appropriate Business Unit Performance Factor to the C&LD
Committee. There may also be other factors significantly affecting STAR business unit results positively or negatively which can
be considered by the STAR Committee when making its recommendation. No member of the STAR Committee makes any
recommendation or determination as to their own STAR award. As a result, there are certain instances in which a Business Unit
Performance Factor recommendation to the C&LD Committee must be made exclusively by the Chief Executive Officer.
Business Unit leaders may then allocate the approved STAR Business Unit Factors among the divisions of the Business Unit to
more closely align the STAR award with performance, so long as the total expenditure does not exceed that approved by the
STAR Committee and no individual STAR award exceeds 200% of target.
• The Total Company Performance Factor is weighted at 30% and is based on the total Company’s success during the fiscal
year and ranges from 0% to 200%, with a target of 100%. The same Total Company Performance Factor is applied to all STAR
award calculations, regardless of STAR business unit. It is determined using a matrix which compares results against pre-
established goals for fiscal year organic sales growth and core earnings per share (“EPS”) growth for the fiscal year.
While the STAR Committee makes recommendations to the C&LD Committee regarding the Business Unit and Total Company
performance factors to be applied to all STAR awards (except those for the STAR Committee members), only the final award
amounts for principal officers are approved specifically by the C&LD Committee. The C&LD Committee has delegated the approval
of STAR awards for other participants to the Chief Executive Officer. The C&LD Committee has discretion to use, increase or
decrease the performance factors recommended by the STAR Committee and/or to choose not to pay STAR awards during a given
year.
III. TIMING AND FORM
STAR awards are determined after the close of the fiscal year and are paid on or about September 15. The award form choices and
relevant considerations are explained to participants annually. Participants receive written notice of their award detailing the
calculation and grant letters for those employees who elect to receive awards in stock options.
Generally, STAR awards are paid in cash. However, before the end of the calendar year preceding the award date, eligible
participants can elect to receive their STAR award in forms other than cash. Alternatives to cash include stock options, stock
appreciation rights (“SARs”), restricted stock units (“RSUs”), local deferral programs (depending on local regulations in some
countries) and/or deferred compensation (for employees eligible to participate in the Executive Deferred Compensation Program).
The number of stock options or SARs awarded to each employee will be determined on grant date by determining the USD value of
the award chosen by the employee to be paid in stock options and dividing that value by the grant date GAAP expense of one stock
option. The result will be rounded up to the nearest whole share. Any STAR award paid in stock options or other form of equity shall
be awarded pursuant to this program and the terms and conditions of the 2025 Plan or any successor stock plan approved in
accordance with applicable listing
STAR Program Summary FY 2026-27 – Approved August 11, 2026

-- 35 of 84 --

standards, as they may be revised from time to time. STAR awards paid in stock options or SARs will have the following terms
unless otherwise approved by the C&LD Committee at grant:
Grant date will be the last business day on or before September 15. If the New York Stock Exchange is closed on the day of the
grant, then the C&LD Committee will establish a grant date as soon as practical following the date previously specified. Provided
participants remain in compliance with the terms and conditions set forth in the currently active Stock Plan and the Regulations,
STAR stock options and SARs are not forfeitable, will become exercisable three years after the grant date, and will expire ten years
after the grant date. In the event of death of the participant, the award becomes exercisable as of the date of death and the award
remains exercisable until the Expiration Date. For awards granted in France or the United Kingdom, the consequences of death are
determined by the local plan supplement, if applicable.
The option price used for any STAR Award will be the closing price for a share of Common Stock on the New York Stock Exchange
on the grant date, or such higher price as may be specified in the French Addendum of the Regulations (the “Grant Price”).
IV. SEPARATION FROM THE COMPANY
• Retirement, Death or Special Separation Agreement: If a participant worked at least 1 day during the fiscal year, the STAR
award is pro-rated by dividing the number of calendar days the participant was an “active employee” during the fiscal year by
365.
• Voluntary Resignation or Termination for Cause: Separating employees must have been active employees as of June 30 or
the last business day in June (the close of the fiscal year for which the award is payable) to receive an award.
• Separation due to a Company authorized divestiture: In the case of divestitures the CHRO is authorized to determine the
appropriate STAR payout based on Business Unit factors either at Target or at projected or actual business results. The CHRO
is also authorized to pay awards for the current or following partial fiscal year at time of divestiture close for administrative
convenience.
Eligible participants who have left the Company will receive a cash payment (stock options can only be issued to active employees)
on the same timing as STAR awards or as soon thereafter as possible.
V. CHANGE IN CONTROL
Notwithstanding the foregoing, if there is a Change in Control in any fiscal year, STAR awards will be calculated in accordance with
Section II above, but each factor will be calculated for the period from the beginning of the fiscal year in which a Change in Control
occurred up to and including the date of such Change in Control (“CIC Period”). “Change in Control” shall have the same meaning
as defined in the 2025 Plan or any successor stock plan.
VI. GENERAL TERMS AND CONDITIONS
While any STAR award amount received by one individual for any year shall be considered as earned remuneration in addition to
salary paid, it shall be understood that this plan does not give to any officer or employee any contract rights, express or implied,
against any Company for any STAR award or for compensation in addition to the salary paid to him or her, or any right to question
the action of the Board of Directors or the C&LD or STAR Committees.
STAR Program Summary FY 2026-27 – Approved August 11, 2026

-- 36 of 84 --

The Chief Human Resources Officer or the Chief Legal Officer may withhold a STAR award for a separated employee who is
discovered to have engaged in serious misconduct or actions detrimental to the Company’s interests. Awards to Section 16 Officers
are subject to the Dodd-Frank Recoupment Policy as adopted by the C&LD Committee, while awards to all other Band 7 and above
executives are subject to the Senior Executive Recoupment Policy as adopted by the C&LD Committee.
To the extent applicable, it is intended that STAR comply with the provisions of Section 409A. STAR will be administered and
interpreted in a manner consistent with this intent. Neither a Participant nor any of a Participant’s creditors or beneficiaries will have
the right to subject any deferred compensation (within the meaning of Section 409A) payable under STAR to any anticipation,
alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A,
any deferred compensation (within the meaning of Section 409A) payable to a Participant under STAR may not be reduced by, or
offset against, any amount owing by a Participant to the Company.
This program document may be amended at any time by the C&LD Committee.
STAR Program Summary FY 2026-27 – Approved August 11, 2026

-- 37 of 84 --

Exhibit 10-3
Form of STAR Stock Option Award Agreement

-- 38 of 84 --

2025 STOCK AND INCENTIVE COMPENSATION PLAN
AWARD AGREEMENT
______________________________________________________________________________
%%FIRST_NAME_LAST_NAME%-%
%%EMPLOYEE_IDENTIFIER%-%
NON-STATUTORY STOCK OPTION SERIES 	%%GRANT_USER_DEFINED_FIELD_2%-%
This grant notice documents an award (the “Award”) of a non-statutory stock option (“Option”) under The Procter &
Gamble 2025 Stock and Incentive Compensation Plan (the “Plan”), subject to the terms and conditions of the Plan, the
Regulations of the Compensation and Leadership Development Committee of the Board of Directors (“Committee”), and
as set forth in this Award Agreement (including any Attachments hereto and the Exercise Instructions in place as may be
revised from time to time).
Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan.
Summary of Award Terms
Option
Price per
Share:
%%OPTION_PRICE,'$999,999,999.99'%-%
Number
of
Shares:
%%TOTAL_SHARES_GRANTED,'999,999,999'%-
%
Grant
Date:
%%OPTION_DATE,'DD-Month-YYYY'%-%
Expiration
Date:
%%EXPIRE_DATE_PERIOD1,'DD-Month-
YYYY'%-%
Vest
Date:
%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-
%
Option Price per Share: 	%%OPTION_PRICE,'$999,999,999.99'%-%
Number of Shares : 	%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Grant Date: 	%%OPTION_DATE,'DD-Month-YYYY'%-%
Expiration Date: 	%%EXPIRE_DATE_PERIOD1,'DD-Month-YYYY'%-%
Vest Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
You may access the Plan by activating this hyperlink: The Procter & Gamble 2025 Stock and Incentive Compensation
Plan and the Regulations and Sub Plans by activating this hyperlink: Regulations of the Committee. If you have difficulty
accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.
1. Vesting and Exercise. As long as you remain in compliance with the terms of the Plan and the Regulations, this
Award will not be forfeitable, will become exercisable on the Vest Date, and will expire on the Expiration Date. In the
event of death, the Vest Date for this Award becomes your date of death and the Award remains exercisable until the
Expiration Date.

-- 39 of 84 --



-- 40 of 84 --

2. 	Restrictive Covenants. By accepting this Award, you agree to be bound by the
restrictive covenants outlined in Attachment B hereto (as may be modified by Attachment C hereto).
3. 	Entire Agreement. This Award Agreement, including Attachment A, Attachment B, Attachment C, and the Plan and
the Regulations of the Committee together constitute an agreement between the Company and you in accordance
with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with
the Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan and
Attachment B of this Award Agreement, must be brought in any federal or state court located in Hamilton County,
Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from
said courts solely for legal actions related to this Award.
You do not need to do anything further to accept this Award under the terms of the Plan. Attachment D is a copy of the
Employee Acknowledgement and Consent Form that you completed when you elected to receive your STAR award in
options.
THE PROCTER & GAMBLE COMPANY
Bala Purushothaman
Chief Human Resources Officer

-- 41 of 84 --

Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the
Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company
reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended
or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established
voluntarily by The Procter & Gamble Company (“P&G”), it is discretionary in nature and it may be amended, suspended
or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any
contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted
repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my
participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected
compensation or salary for any purposes including, but not limited to, calculating any termination, severance,
resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or
similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment
relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my
employer (“Employer”); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted
with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not
create a right to further employment with my Employer and shall not interfere with the ability of my Employer to terminate
my employment relationship at any time, with or without cause; and ix) no claim or entitlement to compensation or
damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I
irrevocably release P&G and my Employer from any such claim that may arise.
Data Privacy
I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my
personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble
Company and its subsidiaries and affiliates (“P&G”) for the exclusive purpose of implementing, administering and
managing my participation in the Plan.
I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my
name, home address and telephone number, date of birth, social insurance number or other identification number,
salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other
entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the
purpose of implementing, administering and managing the Plan (“Data”). I understand that Data may be transferred to
any third parties assisting in the implementation, administration and management of the Plan, that these recipients

-- 42 of 84 --

may be located in my country or elsewhere (including countries outside the European Economic Area), and that the
recipient’s country may have different data privacy laws and protections than my country. I understand that I may request
a list with the names and addresses of any potential recipients of the Data by contacting my local human resources
representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other
form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite
transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of
stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary
to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data,
request additional information about the storage and processing of Data, require any necessary amendments to Data or
refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources
representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the
Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I
may contact my local human resources representative.
Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax,
payment on account or other tax-related withholding (“Tax-Related Items”), I acknowledge that the ultimate liability for all
Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or
undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the
issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or
dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit
to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my
Employer to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I
authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash
compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in
addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the
withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount
of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount
of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or
my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the
exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items
as described in this section.

-- 43 of 84 --

Attachment B – Restrictive Covenants
Participant Obligations. In addition to such other conditions as may be established by the Committee, in consideration
of the granting of an Award under the terms of the Plan, I agree that I am subject to clauses (a) through (d) below and
the other requirements set forth herein and in the Plan, including Article 6, provided, however, that such clauses may be
modified or not applicable as set forth in the U.S. Non-Compete Addendum referenced in Attachment C to the Award
Agreement. Finally, notwithstanding the foregoing, if I reside in a jurisdiction where the restrictions in this Attachment B
are unenforceable, such provisions shall not apply to me.
(a) [Reserved]
(b) [Reserved]
(c) [Reserved]
(d) Subject to the provisions of the section below titled “Defend Trade Secrets Act of 2016”:
i. because a main purpose of the Plan is to strengthen the alignment of interests between employees of P&G and
its shareholders to ensure the continued success of P&G, I acknowledge and agree that I will not take any action
that is significantly contrary to the best interests of P&G. For purposes of this Attachment B, an action taken
“significantly contrary to the best interests of P&G” includes, without limitation, any action taken or threatened by
me that the Committee determines has, or is reasonably likely to have, a significant adverse impact on the
reputation, goodwill, stability, operation, personnel retention and management, or business of P&G;
ii. the provisions of this Attachment B are not in lieu of, but are in addition to, my continuing obligations (which I
acknowledge and agree by accepting any Award under the Plan) to not use or disclose P&G’s confidential and
proprietary trade secret information known to me until any particular confidential and proprietary trade secret
information becomes generally known (through no fault of my own), whereupon the restriction on use and
disclosure shall cease as to that item. Information regarding products in development, in test marketing or being
marketed or promoted in a discrete geographic region, which information P&G is considering for broader use,
shall not be deemed generally known until such broader use is actually commercially implemented. As used in
this Attachment B, “generally known” means known throughout the domestic United States industry or, in the case
of any Participant who has job responsibilities outside of the United States, the appropriate foreign country or
countries’ industry;
iii. by acceptance of any Award granted under the terms of the Plan, I acknowledge and agree that if I was, without
authority, to use or disclose, or threaten to use or disclose, P&G’s confidential and proprietary trade secret
information or violate or threaten to violate any other covenant of this Attachment B, P&G would be entitled to
injunctive and other appropriate relief to prevent me from doing so. I acknowledge and agree that the harm
caused to P&G by the breach or anticipated breach of this Attachment B is by its nature irreparable because,
among other things, it is not readily susceptible of proof as to the monetary harm that would ensue. I consent that
any interim or final equitable relief entered by a court of

-- 44 of 84 --

competent jurisdiction shall, at the request of P&G, be entered on consent and enforced by any court having
jurisdiction over me, without prejudice to any rights either party may have to appeal from the proceedings which
resulted in any grant of such relief; and
iv. I acknowledge and agree that if I am subject to P&G’s Dodd-Frank Compensation Recoupment Policy, P&G’s
Senior Executive Officer Recoupment Policy, and/or any successor policy or similar policy, then such policy
applies with respect to Awards under the Plan and is in addition to all other restrictions and remedies set forth
herein and in this Attachment B and the Plan.
Defend Trade Secrets Act of 2016. Notwithstanding the requirements of confidentiality contained herein and in Article 6
of the Plan, the federal Defend Trade Secrets Act of 2016 immunizes me against criminal and civil liability under federal
or state trade secret laws for my disclosure of trade secrets that is made (i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a
suspected violation of law; (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is
made under seal; or (iii) to my attorney for use in a lawsuit alleging retaliation for reporting a suspected violation of law,
provided that any document containing the trade secret is filed under seal and I do not otherwise disclose the trade
secret, except pursuant to court order. Additionally, nothing contained in this Attachment B or Article 6 of the Plan
prohibits me from: (1) reporting possible violations of federal law or regulations, including any possible securities laws
violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S.
Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (2) making any other
disclosures that are protected under the whistleblower provisions of federal law or regulations; or (3) otherwise fully
participating in any federal whistleblower programs, including but not limited to any such programs managed by the U.S.
Securities and Exchange Commission and/or the Occupational Safety and Health Administration. I do not need prior
authorization from P&G to make any such reports or disclosures and am not required to notify P&G about such
disclosures. If any of the provisions contained in this Attachment B or Article 6 of the Plan shall for any reason, whether
by application of existing law or law which may develop after my acceptance of an Award under the Plan be determined
by a court of competent jurisdiction to be overly broad as to scope of activity, duration, or territory, I agree to join P&G in
requesting such court to construe such provision by limiting or reducing it so as to be enforceable to the extent
compatible with then applicable law. If any one or more of the terms, provisions, covenants, or restrictions of this
Attachment B or Article 6 of the Plan shall be determined by a court of competent jurisdiction to be invalid, void, or
unenforceable, then the remainder of the terms, provisions, covenants, and restrictions of this Attachment B and Article 6
of the Plan shall remain in full force and effect and shall in no way be affected, impaired, or invalidated.
Attachment C – Market Supplemental Information
The following table contains additional terms and conditions and disclosures required for your home and/or host market.
All Market Supplemental Information documents are links to the actual documents.

-- 45 of 84 --

Home Market 	Host Market 	Document Name
US 	US 	U.S. Non-Compete Addendum
Any 	Any 	Review disclosures related to the “All Markets” section of the
following document:
Appendix of Market Specific Terms and Conditions
Any 	Australia, Austria, Azerbaijan,
Belgium, Brazil, Bulgaria, Canada,
Chile, China, Columbia, Costa Rica,
Croatia, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France,
Germany, Greece, Guatemala, Hong
Kong, Hungary, India, Indonesia,
Ireland, Israel, Italy, Japan,
Kazakhstan, Latvia, Malaysia,
Mexico, Morocco, Netherlands,
Nigeria, Pakistan, Panama, Peru,
Philippines, Poland, Portugal,
Romania, Russia, Saudi Arabia,
Serbia, Singapore, Slovak Republic,
South Africa, South Korea Spain,
Sweden, Switzerland, Taiwan,
Thailand, Turkey, Ukraine, United
Arab Emirates, United Kingdom,
Vietnam
Review the specific disclosure relevant to your host location in
the following document:
Appendix of Market Specific Terms and Conditions
Appendix of Employee Supplemental Information (Tax -
Options)
Any 	Canada 	PG Annual Report
Not US 	All except US 	Estate Tax Treatment
Switzerland (Home or Host) 	Swiss Tax Treatment
Attachment D - Employee Acknowledgement and Consent
This Employee Acknowledgement and Consent Form must be completed before you can choose stock awards in lieu of
cash under the STAR Program. To finish your selection, please read the following and click either the I Agree or I
Disagree buttons below.
I understand and agree that I am electing to receive part or all of my STAR award as a stock award under The Procter &
Gamble 2025 Stock and Incentive Compensation Plan (the "Plan"). I acknowledge and agree that my election is subject
to this Employee Acknowledgement and Consent Form and to the terms of the Plan, but excluding the non-compete
provision of Section 6.1(b) of the Plan. The stock award is also subject to and bound by the actions of the Compensation
and Leadership Development Committee and of the Company's Board of Directors. This stock award and the Plan
together constitute an agreement between the Company and me in accordance with the terms thereof and hereof, and
no other understandings and/or agreements have been entered by me with the

-- 46 of 84 --

Company regarding this specific stock option election. Any legal action related to this option grant may be brought in any
federal or state court located in Hamilton County, Ohio, USA, and I hereby agree to accept the jurisdiction of these
courts and consent to service of process from said courts solely for legal actions related to this stock award.
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the
Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company
reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended
or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established
voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended
or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any
contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted
repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my
participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected
compensation or salary for any purposes including, but not limited to, calculating any termination, severance,
resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or
similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment
relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my
employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted
with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not
create a right to further employment with my employer and shall not interfere with the ability of my Employer to terminate
my employment relationship at any time, with or without cause; and ix) no claim or entitlement to compensation or
damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I
irrevocably release P&G and my Employer from any such claim that may arise.
Data Privacy
I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my
personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble
Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and
managing my participation in the Plan.
I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my
name, home address and telephone number, date of birth, social insurance number or other identification number,
salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other

-- 47 of 84 --

entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the
purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to
any third parties assisting in the implementation, administration and management of the Plan, that these recipients may
be located in my country or elsewhere (including countries outside the European Economic Area), and that the
recipient's country may have different data privacy laws and protections than my country. I understand that I may request
a list with the names and addresses of any potential recipients of the Data by contacting my local human resources
representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other
form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite
transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of
stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary
to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data,
request additional information about the storage and processing of Data, require any necessary amendments to Data or
refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources
representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the
Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I
may contact my local human resources representative.
Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax,
payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all
Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or
undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the
issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or
dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit
to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my
Employer to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I
authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash
compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in
addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the
withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount
of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount
of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or
my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the

-- 48 of 84 --

exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items
as described in this section.
To elect part or all of your STAR award as a stock award, please read and click the button below:
I have read, understand and agree to be bound by the terms of:
• This Employee Acknowledgement and Consent Form, and
• The Procter & Gamble 2025 Stock and Incentive Compensation Plan
I Agree
If you do not wish to elect part or all of your STAR award as a stock award, then please read and click the
button below:
I have read and understand the terms noted above.
I do not agree to be bound by these terms, and hereby do not wish to elect part or all of my STAR award as a stock
award.

-- 49 of 84 --

Exhibit 10-4
Form of PSU Award Agreement

-- 50 of 84 --

2025 STOCK AND INCENTIVE COMPENSATION PLAN
AWARD AGREEMENT
______________________________________________________________________________
%%FIRST_NAME_LAST_NAME%-%
%%EMPLOYEE_IDENTIFIER%-%
Subject: PERFORMANCE STOCK UNIT 2026-2029-PSP
This grant notice documents an award (the “Award”) of Performance Stock Units (“PSUs”) under The Procter & Gamble
2025 Stock and Incentive Compensation Plan (the "Plan"), subject to the terms and conditions of the Plan, the
Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), and
as set forth in this Award Agreement (including any Attachments).
Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan.
Summary of Award Terms
Target Number of Units: 	%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Maximum Payout Percentage: 	200%
Conversion Ratio: 	1 PSU = 1 Common Share
Grant Date: 	%%OPTION_DATE,'DD-Month-YYYY'%-%
Vest Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Performance Period: 	1-July-2026 to 30-June-2029
Original Settlement Date (Shares
Delivered on):
8/21/2029
Acceptance Deadline: 	%%GRANT_USER_DEFINED_FIELD_13%-%
You may access the Plan by activating this hyperlink: The Procter & Gamble 2025 Stock and Incentive Compensation
Plan and the Regulations and Sub Plans by activating this hyperlink: Regulations of the Committee.If you have difficulty
accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.

-- 51 of 84 --

Voting Rights and Dividend Equivalents
As a holder of PSUs, during the period from the Grant Date until the date the PSUs are paid, each time a cash dividend
or other cash distribution is paid with respect to Common Stock, you will receive additional PSUs ("Dividend Equivalent
PSUs"). The number of Dividend Equivalent PSUs will be determined as follows: multiply the number of PSUs and
Dividend Equivalent PSUs currently held by the per share amount of the cash dividend or other cash distribution on
Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution.
These Dividend Equivalent PSUs will be subject to the same terms and conditions as the original PSUs that gave rise to
them, including performance vesting and settlement terms, except that if there is a fractional number of Dividend
Equivalent PSUs on the date the PSUs are paid, the resulting fractional share units may be paid as cash, fractional
shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award
represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or
dividend rights as a shareholder.
Performance Vesting
a. Your Target Number of Units indicated in this Award Agreement (the "Target Units") will vest depending upon
performance during the Performance Period, as specified below. This Award Agreement also sets forth the
Maximum Payout Percentage that you may receive pursuant to this Award. Your right to receive all, any portion
of, or more than the Target Units (but in no event more than the Maximum Payout Percentage) will be contingent
upon the achievement of specified levels of certain performance goals measured over the Performance Period.
The applicable performance goals and the payout factors for each performance goal applicable to your Award for
the Performance Period are set forth in the PSP Performance and Payout Factors attachment.
b. Within 60 days following the end of the Performance Period, the Committee will determine (i) whether and to what
extent the performance goals have been satisfied for the Performance Period, (ii) the number of PSUs that shall
become deliverable under this Award, and (iii) whether the other applicable conditions for receipt of shares of
Common Stock in respect of the PSUs have been met. Any PSUs not approved by the Committee in accordance
with this paragraph will be forfeited and cancelled.
Vesting and Payment
If you remain employed through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed
Settlement Date (as defined below). If you leave your Employer before the Vest Date, the Award will be forfeited unless
you meet one of the conditions listed below. For the purposes of this Award, termination of employment will be effective
as of the date that you are no longer actively employed and will not be extended by any notice period required under
local law.
1. Termination on Account of Death. In the event of death, the Award is not forfeited and will become deliverable
on the Settlement Date or Agreed Settlement Date, whichever is applicable.
2. Termination for a Qualified Reason Listed Below. In the event you terminate employment for one of the
qualified reasons listed below, after the Grant Date but before the four-week anniversary of the Grant Date, the
Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after the
four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant

-- 52 of 84 --

Date, the Award will be prorated based on the number of days you remained an employee between the Grant
Date and the one-year anniversary of the Grant Date. If the termination for one of the qualified reasons listed
below occurs after the one-year anniversary of the Grant Date, the entire Award will be retained. The portion of
the Award that is ultimately retained will be delivered on the Original Settlement Date or Agreed Settlement Date,
whichever is applicable, as long as you remain in compliance with the terms of the Plan, this Award Agreement,
and the Regulations. Qualified termination reasons are as follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement with your Employer, the Company or their Subsidiaries
and affiliates (collectively, “P&G”) that provides for equity retention; or
• Termination in connection with a divestiture or separation of any of the P&G’s businesses.
Notwithstanding the foregoing, in the event of a Change in Control, this Award shall be treated according to the terms
provided in the Plan.
Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by
the Committee pursuant to the Plan, subject to applicable tax withholding.
Deferral Election (Applicable to participants Band 7 and above as of the Award Date) At any time at least six
months prior of the end of the Performance Period and so long as the achievement of the applicable performance goals
are not yet readily ascertainable (but in no event later than your Termination of Employment from the Company), you
and the Company may agree to postpone the Original Settlement Date to such later date ("Agreed Settlement Date") as
may be elected by you, which date shall be at least five years later than the Original Settlement Date and in accordance
with Internal Revenue Code Section 409A.
Restrictive Covenants. By accepting this Award, you agree to be bound by the restrictive covenants outlined in
Attachment B hereto (as may be modified by Attachment C hereto).
Entire Agreement. This Award Agreement including Attachment A, Attachment B, Attachment C, the PSP Performance
and Payout Factors, and the Plan and Regulations of the Committee together constitute an agreement between the
Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements
that have been entered by you with the Company regarding this specific Award. Unless otherwise required by local law,
any legal action related to this Award, including Article 6 of the Plan and Attachment B of this Award Agreement, to the
extent applicable, may be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby
agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions
related to this Award. You have the right to consult with a lawyer before accepting this Award.
THE PROCTER & GAMBLE COMPANY
Bala Purushothaman
Chief Human Resources Officer

-- 53 of 84 --

IMPORTANT
By accepting this award within your E*TRADE account, you agree to be bound by the following:
1. The Procter & Gamble 2025 Stock Plan
2. the Stock Plan Regulations of the Committee,
3. This Award Agreement including Attachments A, B and C, and to the extent applicable to you as set forth in
Attachments B and C, the non-compete and non-solicitation clauses.
4. and the attached PSP Performance Factors and Payout Formula.

-- 54 of 84 --

Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the
Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company
reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended
or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established
voluntarily by the Company, it is discretionary in nature, and it may be amended, suspended or terminated at any time; ii)
Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to
receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all
decisions with respect to future Awards, if any, will be at the sole discretion of the Company; iv) my participation in the
Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for
any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of
service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that
my Employer is not the Company, but rather an affiliate or a Subsidiary, the Award will not be interpreted to form an
employment relationship with the Company; and furthermore, the Award will not be interpreted to form an employment
contract with your Employer; vii) the future value of the shares purchased under the Plan is unknown and cannot be
predicted with certainty, may increase or decrease in value, and potentially have no value; viii) my participation in the
Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my
Employer to terminate my employment relationship at any time, with or without cause; and ix) no claim or entitlement to
compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares
purchased and I irrevocably release the Company, my Employer, and their affiliates and Subsidiaries from any such
claim that may arise.
Data Privacy
P&G collects and processes your personal data in line with applicable laws and regulations and in accordance with
P&G’s Global Employee Privacy Policy. I hereby explicitly consent to the collection, use, and transfer, in electronic or
other form, of my personal data as described in this document for purposes of implementing, administering, and
managing my participation in the Plan.
I understand that P&G holds certain personal information about me, including, but not limited to, my name, home
address and telephone number, date of birth, social insurance number or other identification number, salary, nationality,
job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of
stock awarded, canceled, exercised, vested, unvested, or outstanding in my favor, for the purpose of implementing,
administering, and managing the Plan (“Data”). I understand that Data may be transferred to any third parties assisting
in the implementation, administration, and

-- 55 of 84 --

management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside
the European Economic Area), and that the recipient’s country may have different data privacy laws and protections than
my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data
by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and
transfer the Data, in electronic or other form, for the purposes of implementing, administering, and managing my
participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party
with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand
that Data will be held only as long as is necessary to implement, administer, and manage my participation in the Plan. I
understand that I may, at any time, view Data, request additional information about the storage and processing of Data,
require any necessary amendments to Data, or refuse or withdraw the consents herein, in any case without cost, by
contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my
consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to
consent or withdrawal of consent, I understand that I may contact my local human resources representative.
Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax,
payment on account or other tax-related withholding (“Tax-Related Items”), I acknowledge that the ultimate liability for all
Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or
undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the
issuance, vesting, exercise, settlement, subsequent sale of shares acquired, receipt of any dividends or dividend
equivalents, or potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure
the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my
Employer to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I
authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash
compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in
addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the
withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount
of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount
of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or
my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the
exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items
as described in this section.
Attachment B – Restrictive Covenants
Participant Obligations. In addition to such other conditions as may be established by the Committee, in consideration
of the granting of an Award under the terms of the Plan, I agree that I am subject to clauses (a) through (d) below and
the other requirements set forth herein

-- 56 of 84 --

and in the Plan, including Article 6, provided, however, that such clauses may be modified or not applicable as set forth
in the U.S. Non-Compete Addendum referenced in Attachment C to the Award Agreement. Finally, notwithstanding the
foregoing, if I reside in a jurisdiction where the restrictions in this Attachment B are unenforceable, such provisions shall
not apply to me.
(a) The right to exercise any Option or SAR may be conditional upon my certification at the time of exercise whether I
either intend to remain in the employ of P&G for at least one (1) year following the date of exercise of the Option or SAR
or intend to leave P&G within one (1) year following the date of exercise of the Option or SAR, but have no intention to
engage in any activity that would violate the non-compete provisions contained herein.
(b) To better protect the goodwill of P&G and to prevent the disclosure of P&G’s confidential and proprietary trade secret
information and thereby help ensure the long-term success of the business, I acknowledge and agree that, without prior
written consent of the Chief Human Resources Officer and Chief Legal Officer of the Company, I will not engage in any
activity or provide any services, whether as a director, owner (other than as a passive investor holding less than 5% of
an enterprise), manager, supervisor, employee, adviser, consultant or otherwise, for a period of two (2) years following
the date of my Termination of Employment, in connection with the manufacture, development, advertising, promotion, or
sale of any product which is the same as or similar to or competitive with any products of P&G (including both existing
products as well as products known to me, as a consequence of my employment with P&G, to be in development) in any
jurisdiction throughout the world, it being acknowledged that P&G’s business activities are global in nature:
i. with respect to which my work has been directly concerned at any time during the two (2) years preceding
Termination of Employment, or
ii. with respect to which I, as a consequence of my job performance and duties, acquired knowledge of confidential
and proprietary trade secret information of P&G.
For purposes of this Attachment B, it shall be conclusively presumed that I have knowledge of any and all information
that I was directly exposed to through actual receipt or review of memos or documents containing such information or
through actual attendance at meetings at which such information was discussed or disclosed.
(c) To better protect P&G’s investment in its employees and to ensure the long-term success of the business, I
acknowledge and agree that, without prior written consent of P&G, I will not attempt, directly or indirectly, to induce any
employee of P&G to be employed or perform services elsewhere or attempt directly or indirectly to solicit the trade or
business of any customer or partner of P&G for a period of five (5) years following the date of my Termination of
Employment.
(d) Subject to the provisions of the section below titled “Defend Trade Secrets Act of 2016”:
i. because a main purpose of the Plan is to strengthen the alignment of interests between employees of P&G and
its shareholders to ensure the continued success of P&G, I acknowledge and agree that I will not take any action
that is significantly contrary to the best interests of P&G. For purposes of this Attachment B, an action taken
“significantly contrary to the best interests of P&G” includes, without limitation, any action taken or

-- 57 of 84 --

threatened by me that the Committee determines has, or is reasonably likely to have, a significant adverse impact
on the reputation, goodwill, stability, operation, personnel retention and management, or business of P&G;
ii. the provisions of this Attachment B are not in lieu of, but are in addition to, my continuing obligations (which I
acknowledge and agree by accepting any Award under the Plan) to not use or disclose P&G’s confidential and
proprietary trade secret information known to me until any particular confidential and proprietary trade secret
information becomes generally known (through no fault of my own), whereupon the restriction on use and
disclosure shall cease as to that item. Information regarding products in development, in test marketing or being
marketed or promoted in a discrete geographic region, which information P&G is considering for broader use,
shall not be deemed generally known until such broader use is actually commercially implemented. As used in
this Attachment B, “generally known” means known throughout the domestic United States industry or, in the case
of any Participant who has job responsibilities outside of the United States, the appropriate foreign country or
countries’ industry;
iii. by acceptance of any Award granted under the terms of the Plan, I acknowledge and agree that if I was, without
authority, to use or disclose, or threaten to use or disclose, P&G’s confidential and proprietary trade secret
information or violate or threaten to violate any other covenant of this Attachment B, P&G would be entitled to
injunctive and other appropriate relief to prevent me from doing so. I acknowledge and agree that the harm
caused to P&G by the breach or anticipated breach of this Attachment B is by its nature irreparable because,
among other things, it is not readily susceptible of proof as to the monetary harm that would ensue. I consent that
any interim or final equitable relief entered by a court of competent jurisdiction shall, at the request of P&G, be
entered on consent and enforced by any court having jurisdiction over me, without prejudice to any rights either
party may have to appeal from the proceedings which resulted in any grant of such relief; and
iv. I acknowledge and agree that if I am subject to P&G’s Dodd-Frank Compensation Recoupment Policy, P&G’s
Senior Executive Officer Recoupment Policy, and/or any successor policy or similar policy, then such policy
applies with respect to Awards under the Plan and is in addition to all other restrictions and remedies set forth
herein and in this Attachment B and the Plan.
Defend Trade Secrets Act of 2016. Notwithstanding the requirements of confidentiality contained herein and in Article 6
of the Plan, the federal Defend Trade Secrets Act of 2016 immunizes me against criminal and civil liability under federal
or state trade secret laws for my disclosure of trade secrets that is made (i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a
suspected violation of law; (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is
made under seal; or (iii) to my attorney for use in a lawsuit alleging retaliation for reporting a suspected violation of law,
provided that any document containing the trade secret is filed under seal and I do not otherwise disclose the trade
secret, except pursuant to court order. Additionally, nothing contained in this Attachment B or Article 6 of the Plan
prohibits me from: (1) reporting possible violations of federal law or

-- 58 of 84 --

regulations, including any possible securities laws violations, to any governmental agency or entity, including but not
limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any
agency Inspector General; (2) making any other disclosures that are protected under the whistleblower provisions of
federal law or regulations; or (3) otherwise fully participating in any federal whistleblower programs, including but not
limited to any such programs managed by the U.S. Securities and Exchange Commission and/or the Occupational
Safety and Health Administration. I do not need prior authorization from P&G to make any such reports or disclosures
and am not required to notify P&G about such disclosures.
If any of the provisions contained in this Attachment B or Article 6 of the Plan shall for any reason, whether by application
of existing law or law which may develop after my acceptance of an Award under the Plan be determined by a court of
competent jurisdiction to be overly broad as to scope of activity, duration, or territory, I agree to join P&G in requesting
such court to construe such provision by limiting or reducing it so as to be enforceable to the extent compatible with then
applicable law. If any one or more of the terms, provisions, covenants, or restrictions of this Attachment B or Article 6 of
the Plan shall be determined by a court of competent jurisdiction to be invalid, void, or unenforceable, then the
remainder of the terms, provisions, covenants, and restrictions of this Attachment B and Article 6 of the Plan shall remain
in full force and effect and shall in no way be affected, impaired, or invalidated.

-- 59 of 84 --

Attachment C – Market Supplemental Information
The following table contains additional terms and conditions and disclosures required for your home and/or host market.
All Market Supplemental Information documents are links to the actual documents.
Home Market 	Host Market 	Document Name
US 	US 	U.S. Non-Compete Addendum
Any 	Any 	Review disclosures related to the “All Markets” section of the
following document:
Appendix of Market Specific Terms and Conditions
Any 	Australia, Austria, Azerbaijan,
Belgium, Brazil, Bulgaria, Canada,
Chile, China, Columbia, Costa Rica,
Croatia, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France,
Germany, Greece, Guatemala, Hong
Kong, Hungary, India, Indonesia,
Ireland, Israel, Italy, Japan,
Kazakhstan, Latvia, Malaysia,
Mexico, Morocco, Netherlands,
Nigeria, Pakistan, Panama, Peru,
Philippines, Poland, Portugal,
Romania, Russia, Saudi Arabia,
Serbia, Singapore, Slovak Republic,
South Africa, South Korea Spain,
Sweden, Switzerland, Taiwan,
Thailand, Turkey, Ukraine, United
Arab Emirates, United Kingdom,
Vietnam
Review the specific disclosure relevant to your host location in
the following document:
Appendix of Market Specific Terms and Conditions
Appendix of Employee Supplemental Information (Tax -
Options)
Any 	Canada 	PG Annual Report
Not US 	All except US 	Estate Tax Treatment
Switzerland (Home or Host) 	Swiss Tax Treatment

-- 60 of 84 --

Exhibit 10-5
Form of LTIP RSU Agreement

-- 61 of 84 --

2025 STOCK AND INCENTIVE COMPENSATION PLAN
AWARD AGREEMENT
%%FIRST_NAME_MIDDLE_NAME_LAST_NAME%-%
%%EMPLOYEE_IDENTIFIER%-%
Subject: RESTRICTED STOCK UNIT SERIE 	%%GRANT_USER_DEFINED_FIELD_2%-%
This grant notice documents an award (the “Award”) of Restricted Stock Units (“RSUs”) under The Procter & Gamble
2025 Stock and Incentive Compensation Plan (the "Plan"), subject to the terms and conditions of the Plan, the
Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), and
as set forth in this Award Agreement (including any Attachments hereto and the Settlement Instructions in place as may
be revised from time to time).
Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan.
Summary of Award Terms
Number of Restricted Stock Units: 	%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Grant Date Share Price: 	%%MARKET_VALUE%-%
Grant Date: 	%%OPTION_DATE,'DD-Month-YYYY'%-%
Vest Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Original Settlement Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Acceptance Deadline: 	%%GRANT_USER_DEFINED_FIELD_13%-%
You may access the Plan by activating this hyperlink: The Procter & Gamble 2025 Stock and Incentive Compensation
Plan and the Regulations and Sub Plans by activating this hyperlink: Regulations of the Committee. If you have difficulty
accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.
Voting Rights and Dividend Equivalents
As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend
or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent
RSUs"). The number of

-- 62 of 84 --

Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs
currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the
result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will
be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and
settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid,
the resulting fractional share unit may be paid as cash, fractional shares, or rounded up to the nearest full share based
on administrative preference of the Company. You must hold RSUs on the dividend payment date in order to be credited
with Dividend Equivalents. This Award represents an unfunded, unsecured right to receive payment in the future, and
does not entitle you to voting rights or dividend rights as a shareholder.
Vesting and Payment
If you remain employed through the Vest Date, the Award will be paid on the Settlement Date. If you leave your
employer (“Employer”) before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed
below. For the purposes of this Award, termination of employment will be effective as of the date that you are no longer
actively employed and will not be extended by any notice period required under local law.
1. Termination on Account of Death. In the event of death, the Award will be immediately and fully vested, and
payment will be made by the later of the end of the calendar year or two and a half months following the date of
death.
2. Termination for a Qualified Reason Listed Below. In the event you terminate employment for one of the
qualified reasons listed below, after the Grant Date but before the four-week anniversary of the Grant Date, the
Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after the
four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the Award will
be prorated based on the number of days you remained an employee between the Grant Date and the one-year
anniversary of the Grant Date. If the termination for one of the qualified reasons listed below occurs after the one-
year anniversary of the Grant Date, the entire Award will be retained. The portion of the Award that is ultimately
retained will be delivered on the Settlement Date in this Award Agreement as long as you remain in compliance
with the terms of the Plan, this Award Agreement and the Regulations. Qualified termination reasons are as
follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement with your Employer, the Company or their Subsidiaries
and affiliates (collectively, “P&G”) that provides for equity retention; or
• Termination in connection with a divestiture or separation of any of the P&G’s businesses.
Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms
provided in the Plan.

-- 63 of 84 --

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by
the Committee pursuant to the Plan, subject to applicable tax withholding.
Restrictive Covenants. By accepting this Award, you agree to be bound by the restrictive covenants outlined in
Attachment B hereto (as may be modified by Attachment C hereto).
Entire Agreement. This Award Agreement, including Attachment A, Attachment B, Attachment C, and the Plan and the
Regulations of the Committee, together constitute an agreement between the Company and you in accordance with the
terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company
regarding this specific Award. Unless otherwise required by local law, any legal action related to this Award, including
Article 6 of the Plan and Attachment B of this Award Agreement must be brought in any federal or state court located in
Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of
process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer before
accepting this Award.
THE PROCTER & GAMBLE COMPANY
Bala Purushothaman
Chief Human Resources Officer
IMPORTANT
By accepting this award within your E*TRADE account, you agree to be bound by The Procter & Gamble 2025 Stock
Plan, the Stock Plan Regulations of the Committee, this Award Agreement including Attachments A, B, and C. To the
extent applicable to you, as set forth in Attachments B and C, you acknowledge that you are subject to the non-compete
and non-solicitation clauses in these documents.

-- 64 of 84 --

Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the
Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company
reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended
or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established
voluntarily by the Company, it is discretionary in nature, and it may be amended, suspended or terminated at any time; ii)
Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to
receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all
decisions with respect to future Awards, if any, will be at the sole discretion of the Company; iv) my participation in the
Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for
any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of
service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that
my Employer is not the Company, but rather an affiliate or a Subsidiary, the Award will not be interpreted to form an
employment relationship with the Company; and furthermore, the Award will not be interpreted to form an employment
contract with your Employer; vii) the future value of the shares purchased under the Plan is unknown and cannot be
predicted with certainty, may increase or decrease in value, and potentially have no value; viii) my participation in the
Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my
Employer to terminate my employment relationship at any time, with or without cause; and ix) no claim or entitlement to
compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares
purchased and I irrevocably release the Company, my Employer, and their affiliates and Subsidiaries from any such
claim that may arise.
Data Privacy
P&G collects and processes your personal data in line with applicable laws and regulations and in accordance with
P&G’s Global Employee Privacy Policy. I hereby explicitly consent to the collection, use, and transfer, in electronic or
other form, of my personal data as described in this document for purposes of implementing, administering, and
managing my participation in the Plan.
I understand that P&G holds certain personal information about me, including, but not limited to, my name, home
address and telephone number, date of birth, social insurance number or other identification number, salary, nationality,
job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of
stock awarded, canceled, exercised, vested, unvested, or outstanding in my favor, for the purpose of implementing,
administering, and managing the Plan (“Data”). I understand

-- 65 of 84 --

that Data may be transferred to any third parties assisting in the implementation, administration, and management of the
Plan, that these recipients may be located in my country or elsewhere (including countries outside the European
Economic Area), and that the recipient’s country may have different data privacy laws and protections than my country. I
understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting
my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the
Data, in electronic or other form, for the purposes of implementing, administering, and managing my participation in the
Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may
elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be
held only as long as is necessary to implement, administer, and manage my participation in the Plan. I understand that I
may, at any time, view Data, request additional information about the storage and processing of Data, require any
necessary amendments to Data, or refuse or withdraw the consents herein, in any case without cost, by contacting in
writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may
affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or
withdrawal of consent, I understand that I may contact my local human resources representative.
Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax,
payment on account or other tax-related withholding (“Tax-Related Items”), I acknowledge that the ultimate liability for all
Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or
undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the
issuance, vesting, exercise, settlement, subsequent sale of shares acquired, receipt of any dividends or dividend
equivalents, or potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure
the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my
Employer to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I
authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash
compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in
addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the
withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount
of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount
of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or
my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the
exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items
as described in this section.
Attachment B – Restrictive Covenants

-- 66 of 84 --

Participant Obligations. In addition to such other conditions as may be established by the Committee, in consideration
of the granting of an Award under the terms of the Plan, I agree that I am subject to clauses (a) through (d) below and
the other requirements set forth herein and in the Plan, including Article 6, provided, however, that such clauses may be
modified or not applicable as set forth in the U.S. Non-Compete Addendum referenced in Attachment C to the Award
Agreement. Finally, notwithstanding the foregoing, if I reside in a jurisdiction where the restrictions in this Attachment B
are unenforceable, such provisions shall not apply to me.
(a) The right to exercise any Option or SAR may be conditional upon my certification at the time of exercise whether I
either intend to remain in the employ of P&G for at least one (1) year following the date of exercise of the Option or SAR
or intend to leave P&G within one (1) year following the date of exercise of the Option or SAR, but have no intention to
engage in any activity that would violate the non-compete provisions contained herein.
(b) To better protect the goodwill of P&G and to prevent the disclosure of P&G’s confidential and proprietary trade secret
information and thereby help ensure the long-term success of the business, I acknowledge and agree that, without prior
written consent of the Chief Human Resources Officer and Chief Legal Officer of the Company, I will not engage in any
activity or provide any services, whether as a director, owner (other than as a passive investor holding less than 5% of
an enterprise), manager, supervisor, employee, adviser, consultant or otherwise, for a period of two (2) years following
the date of my Termination of Employment, in connection with the manufacture, development, advertising, promotion, or
sale of any product which is the same as or similar to or competitive with any products of P&G (including both existing
products as well as products known to me, as a consequence of my employment with P&G, to be in development) in any
jurisdiction throughout the world, it being acknowledged that P&G’s business activities are global in nature:
i. with respect to which my work has been directly concerned at any time during the two (2) years preceding
Termination of Employment, or
ii. with respect to which I, as a consequence of my job performance and duties, acquired knowledge of confidential
and proprietary trade secret information of P&G.
For purposes of this Attachment B, it shall be conclusively presumed that I have knowledge of any and all information
that I was directly exposed to through actual receipt or review of memos or documents containing such information or
through actual attendance at meetings at which such information was discussed or disclosed.
(c) To better protect P&G’s investment in its employees and to ensure the long-term success of the business, I
acknowledge and agree that, without prior written consent of P&G, I will not attempt, directly or indirectly, to induce any
employee of P&G to be employed or perform services elsewhere or attempt directly or indirectly to solicit the trade or
business of any customer or partner of P&G for a period of five (5) years following the date of my Termination of
Employment.

-- 67 of 84 --

(d) Subject to the provisions of the section below titled “Defend Trade Secrets Act of 2016”:
i. because a main purpose of the Plan is to strengthen the alignment of interests between employees of P&G and
its shareholders to ensure the continued success of P&G, I acknowledge and agree that I will not take any action
that is significantly contrary to the best interests of P&G. For purposes of this Attachment B, an action taken
“significantly contrary to the best interests of P&G” includes, without limitation, any action taken or threatened by
me that the Committee determines has, or is reasonably likely to have, a significant adverse impact on the
reputation, goodwill, stability, operation, personnel retention and management, or business of P&G;
ii. the provisions of this Attachment B are not in lieu of, but are in addition to, my continuing obligations (which I
acknowledge and agree by accepting any Award under the Plan) to not use or disclose P&G’s confidential and
proprietary trade secret information known to me until any particular confidential and proprietary trade secret
information becomes generally known (through no fault of my own), whereupon the restriction on use and
disclosure shall cease as to that item. Information regarding products in development, in test marketing or being
marketed or promoted in a discrete geographic region, which information P&G is considering for broader use,
shall not be deemed generally known until such broader use is actually commercially implemented. As used in
this Attachment B, “generally known” means known throughout the domestic United States industry or, in the case
of any Participant who has job responsibilities outside of the United States, the appropriate foreign country or
countries’ industry;
iii. by acceptance of any Award granted under the terms of the Plan, I acknowledge and agree that if I was, without
authority, to use or disclose, or threaten to use or disclose, P&G’s confidential and proprietary trade secret
information or violate or threaten to violate any other covenant of this Attachment B, P&G would be entitled to
injunctive and other appropriate relief to prevent me from doing so. I acknowledge and agree that the harm
caused to P&G by the breach or anticipated breach of this Attachment B is by its nature irreparable because,
among other things, it is not readily susceptible of proof as to the monetary harm that would ensue. I consent that
any interim or final equitable relief entered by a court of competent jurisdiction shall, at the request of P&G, be
entered on consent and enforced by any court having jurisdiction over me, without prejudice to any rights either
party may have to appeal from the proceedings which resulted in any grant of such relief; and
iv. I acknowledge and agree that if I am subject to P&G’s Dodd-Frank Compensation Recoupment Policy, P&G’s
Senior Executive Officer Recoupment Policy, and/or any successor policy or similar policy, then such policy
applies with respect to Awards under the Plan and is in addition to all other restrictions and remedies set forth
herein and in this Attachment B and the Plan.

-- 68 of 84 --

Defend Trade Secrets Act of 2016. Notwithstanding the requirements of confidentiality contained herein and in Article 6
of the Plan, the federal Defend Trade Secrets Act of 2016 immunizes me against criminal and civil liability under federal
or state trade secret laws for my disclosure of trade secrets that is made (i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a
suspected violation of law; (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is
made under seal; or (iii) to my attorney for use in a lawsuit alleging retaliation for reporting a suspected violation of law,
provided that any document containing the trade secret is filed under seal and I do not otherwise disclose the trade
secret, except pursuant to court order. Additionally, nothing contained in this Attachment B or Article 6 of the Plan
prohibits me from: (1) reporting possible violations of federal law or regulations, including any possible securities laws
violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S.
Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (2) making any other
disclosures that are protected under the whistleblower provisions of federal law or regulations; or (3) otherwise fully
participating in any federal whistleblower programs, including but not limited to any such programs managed by the U.S.
Securities and Exchange Commission and/or the Occupational Safety and Health Administration. I do not need prior
authorization from P&G to make any such reports or disclosures and am not required to notify P&G about such
disclosures.
If any of the provisions contained in this Attachment B or Article 6 of the Plan shall for any reason, whether by application
of existing law or law which may develop after my acceptance of an Award under the Plan be determined by a court of
competent jurisdiction to be overly broad as to scope of activity, duration, or territory, I agree to join P&G in requesting
such court to construe such provision by limiting or reducing it so as to be enforceable to the extent compatible with then
applicable law. If any one or more of the terms, provisions, covenants, or restrictions of this Attachment B or Article 6 of
the Plan shall be determined by a court of competent jurisdiction to be invalid, void, or unenforceable, then the
remainder of the terms, provisions, covenants, and restrictions of this Attachment B and Article 6 of the Plan shall remain
in full force and effect and shall in no way be affected, impaired, or invalidated.

-- 69 of 84 --

Attachment C – Market Supplemental Information
The following table contains additional terms and conditions and disclosures required for your home and/or host market.
All Market Supplemental Information documents are links to the actual documents.
Home Market 	Host Market 	Document Name
US 	US 	U.S. Non-Compete Addendum
Any 	Any 	Review disclosures related to the “All Markets” section of the
following document:
Appendix of Market Specific Terms and Conditions
Any 	Australia, Austria, Azerbaijan,
Belgium, Brazil, Bulgaria, Canada,
Chile, China, Columbia, Costa Rica,
Croatia, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France,
Germany, Greece, Guatemala, Hong
Kong, Hungary, India, Indonesia,
Ireland, Israel, Italy, Japan,
Kazakhstan, Latvia, Malaysia,
Mexico, Morocco, Netherlands,
Nigeria, Pakistan, Panama, Peru,
Philippines, Poland, Portugal,
Romania, Russia, Saudi Arabia,
Serbia, Singapore, Slovak Republic,
South Africa, South Korea Spain,
Sweden, Switzerland, Taiwan,
Thailand, Turkey, Ukraine, United
Arab Emirates, United Kingdom,
Vietnam
Review the specific disclosure relevant to your host location in
the following document:
Appendix of Market Specific Terms and Conditions
Appendix of Employee Supplemental Information (Tax -
Options)
Any 	Canada 	PG Annual Report
Not US 	All except US 	Estate Tax Treatment
Switzerland (Home or Host) 	Swiss Tax Treatment

-- 70 of 84 --

Exhibit 10-6
Form of LTIP Stock Option Award Agreement

-- 71 of 84 --

2025 STOCK AND INCENTIVE COMPENSATION PLAN
AWARD AGREEMENT
NON-STATUTORY STOCK OPTIONS
%%FIRST_NAME_MIDDLE_NAME_LAST_NAME%-%
%%EMPLOYEE_IDENTIFIER%-%
Subject: NON-STATUTORY STOCK OPTION SERIE 	%%GRANT_USER_DEFINED_FIELD_2%-%
This grant notice documents an award (the “Award”) of a non-statutory stock option (“Option”) under The Procter &
Gamble 2025 Stock and Incentive Compensation Plan (the “Plan”), subject to the terms and conditions of the Plan, the
Regulations of the Compensation and Leadership Development Committee of the Board of Directors (“Committee”) and
as set forth in this Award Agreement (including any Attachments hereto and the Exercise Instructions in place as may be
revised from time to time).
Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan.
Summary of Award Terms
Option Price per Share: 	%%OPTION_PRICE,'$999,999,999.99'%-%
Number of Shares: 	%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Grant Date: 	%%OPTION_DATE,'DD-Month-YYYY'%-%
Expiration Date: 	%%EXPIRE_DATE_PERIOD1,'DD-Month-YYYY'%-%
Vest Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Acceptance Deadline: 	%%GRANT_USER_DEFINED_FIELD_13%-%
You may access the Plan by activating this hyperlink: The Procter & Gamble 2025 Stock and Incentive Compensation
Plan and the Regulations and Sub Plans by activating this hyperlink: Regulations of the Committee. If you have difficulty
accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.
Vesting and Exercise. If you remain employed through the Vest Date, the Award will become exercisable on the Vest
Date. If you leave your employer (“Employer”) before the Vest Date, the Award will be forfeited unless you meet
one of the conditions

-- 72 of 84 --

listed below. If you terminate employment before the Expiration Date and prior to exercising the Award, except for the
reasons listed below, the Award will be forfeited immediately upon your termination of employment. For the purposes of
this Award, termination of employment will be effective as of the date that you are no longer actively employed and will
not be extended by any notice period required under local law.
1. Termination on Account of Death. In the event of death, the Vest Date for this Award becomes your date of
death and the Award in its entirety remains exercisable until the Expiration Date.
2. Termination for a Qualified Reason Listed Below. In the event you terminate employment for one of the
qualified reasons listed below, after the Grant Date but before the four-week anniversary of the Grant Date, the
Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after the
four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the Award will
be prorated based on the number of days you remained an employee between the Grant Date and the one-year
anniversary of the Grant Date. If the termination for one of the qualified reasons listed below occurs after the one-
year anniversary of the Grant Date, the entire Award will be retained. The portion of the Award that is ultimately
retained will be exercisable on the Vest Date in this Award Agreement and will expire on the Expiration Date as
long as you remain in compliance with the terms of the Plan, this Award Agreement, and the Regulations.
Qualified termination reasons are as follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement with your Employer, the Company or their Subsidiaries
and affiliates (collectively, “P&G”) that provides for equity retention; or
• Termination in connection with a divestiture or separation of any of P&G’s businesses.
Restrictive Covenants. By accepting this Award, you agree to be bound by the restrictive covenants outlined in
Attachment B hereto (as may be modified by Attachment C hereto).
Entire Agreement. This Award Agreement, including Attachment A, Attachment B, Attachment C, and the Plan and
Regulations of the Committee together constitute an agreement between the Company and you in accordance with the
terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company
regarding this specific Award. Unless otherwise required by local law, any legal action related to this Award, including
Article 6 of the Plan and Attachment B of this Award Agreement, must be brought in any federal or state court located in
Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of
process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer and at
least 14 calendar days to consider before accepting this Award.

-- 73 of 84 --

THE PROCTER & GAMBLE COMPANY
Bala Purushothaman
Chief Human Resources Officer
IMPORTANT
By accepting this award within your E*TRADE account, you agree to be bound by The Procter & Gamble 2025 Stock
Plan, the Stock Plan Regulations of the Committee, and this Award Agreement including Attachments A, B, and C. To the
extent applicable to you, as set forth in Attachments B and C, you acknowledge that you are subject to the non-compete
and non-solicitation clauses in these documents.

-- 74 of 84 --

Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the
Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company
reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended
or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established
voluntarily by the Company, it is discretionary in nature, and it may be amended, suspended or terminated at any time; ii)
Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to
receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all
decisions with respect to future Awards, if any, will be at the sole discretion of the Company; iv) my participation in the
Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for
any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of
service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that
my Employer is not the Company, but rather an affiliate or a Subsidiary, the Award will not be interpreted to form an
employment relationship with the Company; and furthermore, the Award will not be interpreted to form an employment
contract with your Employer; vii) the future value of the shares purchased under the Plan is unknown and cannot be
predicted with certainty, may increase or decrease in value, and potentially have no value; viii) my participation in the
Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my
Employer to terminate my employment relationship at any time, with or without cause; and ix) no claim or entitlement to
compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares
purchased and I irrevocably release the Company, my Employer, and their affiliates and Subsidiaries from any such
claim that may arise.
Data Privacy
P&G collects and processes your personal data in line with applicable laws and regulations and in accordance with
P&G’s Global Employee Privacy Policy. I hereby explicitly consent to the collection, use, and transfer, in electronic or
other form, of my personal data as described in this document for purposes of implementing, administering, and
managing my participation in the Plan.
I understand that P&G holds certain personal information about me, including, but not limited to, my name, home
address and telephone number, date of birth, social insurance number or other identification number, salary, nationality,
job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of
stock awarded, canceled, exercised, vested, unvested, or outstanding in my favor, for the

-- 75 of 84 --

purpose of implementing, administering, and managing the Plan (“Data”). I understand that Data may be transferred to
any third parties assisting in the implementation, administration, and management of the Plan, that these recipients may
be located in my country or elsewhere (including countries outside the European Economic Area), and that the
recipient’s country may have different data privacy laws and protections than my country. I understand that I may request
a list with the names and addresses of any potential recipients of the Data by contacting my local human resources
representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other
form, for the purposes of implementing, administering, and managing my participation in the Plan, including any requisite
transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of
stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary
to implement, administer, and manage my participation in the Plan. I understand that I may, at any time, view Data,
request additional information about the storage and processing of Data, require any necessary amendments to Data, or
refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources
representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the
Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I
may contact my local human resources representative.
Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax,
payment on account or other tax-related withholding (“Tax-Related Items”), I acknowledge that the ultimate liability for all
Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or
undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the
issuance, vesting, exercise, settlement, subsequent sale of shares acquired, receipt of any dividends or dividend
equivalents, or potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure
the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items. Prior to
exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer
to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I authorize
P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash compensation paid
to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible
under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for
Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to
satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items
that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of
shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to
deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this
section.

-- 76 of 84 --

Attachment B – Restrictive Covenants
Participant Obligations. In addition to such other conditions as may be established by the Committee, in consideration
of the granting of an Award under the terms of the Plan, I agree that I am subject to clauses (a) through (d) below and
the other requirements set forth herein and in the Plan, including Article 6, provided, however, that such clauses may be
modified or not applicable as set forth in the U.S. Non-Compete Addendum referenced in Attachment C to the Award
Agreement. Finally, notwithstanding the foregoing, if I reside in a jurisdiction where the restrictions in this Attachment B
are unenforceable, such provisions shall not apply to me.
(a) The right to exercise any Option or SAR may be conditional upon my certification at the time of exercise whether I
either intend to remain in the employ of P&G for at least one (1) year following the date of exercise of the Option or SAR
or intend to leave P&G within one (1) year following the date of exercise of the Option or SAR, but have no intention to
engage in any activity that would violate the non-compete provisions contained herein.
(b) To better protect the goodwill of P&G and to prevent the disclosure of P&G’s confidential and proprietary trade secret
information and thereby help ensure the long-term success of the business, I acknowledge and agree that, without prior
written consent of the Chief Human Resources Officer and Chief Legal Officer of the Company, I will not engage in any
activity or provide any services, whether as a director, owner (other than as a passive investor holding less than 5% of
an enterprise), manager, supervisor, employee, adviser, consultant or otherwise, for a period of two (2) years following
the date of my Termination of Employment, in connection with the manufacture, development, advertising, promotion, or
sale of any product which is the same as or similar to or competitive with any products of P&G (including both existing
products as well as products known to me, as a consequence of my employment with P&G, to be in development) in any
jurisdiction throughout the world, it being acknowledged that P&G’s business activities are global in nature:
i. with respect to which my work has been directly concerned at any time during the two (2) years preceding
Termination of Employment, or
ii. with respect to which I, as a consequence of my job performance and duties, acquired knowledge of confidential
and proprietary trade secret information of P&G.
For purposes of this Attachment B, it shall be conclusively presumed that I have knowledge of any and all information
that I was directly exposed to through actual receipt or review of memos or documents containing such information or
through actual attendance at meetings at which such information was discussed or disclosed.
(c) To better protect P&G’s investment in its employees and to ensure the long-term success of the business, I
acknowledge and agree that, without prior written consent of P&G, I will not attempt, directly or indirectly, to induce any
employee of P&G to be employed or perform services elsewhere or attempt directly or indirectly to solicit the trade or
business of any customer or partner of P&G for a period of five (5) years following the date of my Termination of
Employment.

-- 77 of 84 --

(d) Subject to the provisions of the section below titled “Defend Trade Secrets Act of 2016”:
i. because a main purpose of the Plan is to strengthen the alignment of interests between employees of P&G and
its shareholders to ensure the continued success of P&G, I acknowledge and agree that I will not take any action
that is significantly contrary to the best interests of P&G. For purposes of this Attachment B, an action taken
“significantly contrary to the best interests of P&G” includes, without limitation, any action taken or threatened by
me that the Committee determines has, or is reasonably likely to have, a significant adverse impact on the
reputation, goodwill, stability, operation, personnel retention and management, or business of P&G;
ii. the provisions of this Attachment B are not in lieu of, but are in addition to, my continuing obligations (which I
acknowledge and agree by accepting any Award under the Plan) to not use or disclose P&G’s confidential and
proprietary trade secret information known to me until any particular confidential and proprietary trade secret
information becomes generally known (through no fault of my own), whereupon the restriction on use and
disclosure shall cease as to that item. Information regarding products in development, in test marketing or being
marketed or promoted in a discrete geographic region, which information P&G is considering for broader use,
shall not be deemed generally known until such broader use is actually commercially implemented. As used in
this Attachment B, “generally known” means known throughout the domestic United States industry or, in the case
of any Participant who has job responsibilities outside of the United States, the appropriate foreign country or
countries’ industry;
iii. by acceptance of any Award granted under the terms of the Plan, I acknowledge and agree that if I was, without
authority, to use or disclose, or threaten to use or disclose, P&G’s confidential and proprietary trade secret
information or violate or threaten to violate any other covenant of this Attachment B, P&G would be entitled to
injunctive and other appropriate relief to prevent me from doing so. I acknowledge and agree that the harm
caused to P&G by the breach or anticipated breach of this Attachment B is by its nature irreparable because,
among other things, it is not readily susceptible of proof as to the monetary harm that would ensue. I consent that
any interim or final equitable relief entered by a court of competent jurisdiction shall, at the request of P&G, be
entered on consent and enforced by any court having jurisdiction over me, without prejudice to any rights either
party may have to appeal from the proceedings which resulted in any grant of such relief; and
iv. I acknowledge and agree that if I am subject to P&G’s Dodd-Frank Compensation Recoupment Policy, P&G’s
Senior Executive Officer Recoupment Policy, and/or any successor policy or similar policy, then such policy
applies with respect to Awards under the Plan and is in addition to all other restrictions and remedies set forth
herein and in this Attachment B and the Plan.

-- 78 of 84 --

Defend Trade Secrets Act of 2016. Notwithstanding the requirements of confidentiality contained herein and in Article 6
of the Plan, the federal Defend Trade Secrets Act of 2016 immunizes me against criminal and civil liability under federal
or state trade secret laws for my disclosure of trade secrets that is made (i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a
suspected violation of law; (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is
made under seal; or (iii) to my attorney for use in a lawsuit alleging retaliation for reporting a suspected violation of law,
provided that any document containing the trade secret is filed under seal and I do not otherwise disclose the trade
secret, except pursuant to court order. Additionally, nothing contained in this Attachment B or Article 6 of the Plan
prohibits me from: (1) reporting possible violations of federal law or regulations, including any possible securities laws
violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S.
Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (2) making any other
disclosures that are protected under the whistleblower provisions of federal law or regulations; or (3) otherwise fully
participating in any federal whistleblower programs, including but not limited to any such programs managed by the U.S.
Securities and Exchange Commission and/or the Occupational Safety and Health Administration. I do not need prior
authorization from P&G to make any such reports or disclosures and am not required to notify P&G about such
disclosures.
If any of the provisions contained in this Attachment B or Article 6 of the Plan shall for any reason, whether by application
of existing law or law which may develop after my acceptance of an Award under the Plan be determined by a court of
competent jurisdiction to be overly broad as to scope of activity, duration, or territory, I agree to join P&G in requesting
such court to construe such provision by limiting or reducing it so as to be enforceable to the extent compatible with then
applicable law. If any one or more of the terms, provisions, covenants, or restrictions of this Attachment B or Article 6 of
the Plan shall be determined by a court of competent jurisdiction to be invalid, void, or unenforceable, then the
remainder of the terms, provisions, covenants, and restrictions of this Attachment B and Article 6 of the Plan shall remain
in full force and effect and shall in no way be affected, impaired, or invalidated.

-- 79 of 84 --

Attachment C – Market Supplemental Information
The following table contains additional terms and conditions and disclosures required for your home and/or host market.
All Market Supplemental Information documents are links to the actual documents.
Home Market 	Host Market 	Document Name
US 	US 	U.S. Non-Compete Addendum
Any 	Any 	Review disclosures related to the “All Markets” section of the
following document:
Appendix of Market Specific Terms and Conditions
Any 	Australia, Austria, Azerbaijan,
Belgium, Brazil, Bulgaria, Canada,
Chile, China, Columbia, Costa Rica,
Croatia, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France,
Germany, Greece, Guatemala, Hong
Kong, Hungary, India, Indonesia,
Ireland, Israel, Italy, Japan,
Kazakhstan, Latvia, Malaysia,
Mexico, Morocco, Netherlands,
Nigeria, Pakistan, Panama, Peru,
Philippines, Poland, Portugal,
Romania, Russia, Saudi Arabia,
Serbia, Singapore, Slovak Republic,
South Africa, South Korea Spain,
Sweden, Switzerland, Taiwan,
Thailand, Turkey, Ukraine, United
Arab Emirates, United Kingdom,
Vietnam
Review the specific disclosure relevant to your host location in
the following document:
Appendix of Market Specific Terms and Conditions
Appendix of Employee Supplemental Information (Tax -
Options)
Any 	Canada 	PG Annual Report
Not US 	All except US 	Estate Tax Treatment
Switzerland (Home or Host) 	Swiss Tax Treatment

-- 80 of 84 --

EXHIBIT 31.1
Rule 13a-14(a)/15d-14(a) Certifications
I, Shailesh Jejurikar, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ SHAILESH JEJURIKAR
(Shailesh Jejurikar)
Chairman of the Board, President and Chief Executive Officer
October 22, 2026
Date

-- 81 of 84 --

EXHIBIT 31.2
Rule 13a-14(a)/15d-14(a) Certifications
I, Andre Schulten, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
October 22, 2026
Date

-- 82 of 84 --

EXHIBIT 32.1
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2026 fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ SHAILESH JEJURIKAR
(Shailesh Jejurikar)
Chairman of the Board, President and Chief Executive Officer
October 22, 2026
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 83 of 84 --

EXHIBIT 32.2
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2026 fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
October 22, 2026
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 84 of 84 --